US20050250936A1 - Modified TGF-beta superfamily proteins - Google Patents

Modified TGF-beta superfamily proteins Download PDF

Info

Publication number
US20050250936A1
US20050250936A1 US10/816,768 US81676804A US2005250936A1 US 20050250936 A1 US20050250936 A1 US 20050250936A1 US 81676804 A US81676804 A US 81676804A US 2005250936 A1 US2005250936 A1 US 2005250936A1
Authority
US
United States
Prior art keywords
tgf
protein
proteins
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/816,768
Other languages
English (en)
Inventor
Hermann Oppermann
Mei-Sheng Tai
John McCartney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Priority to US10/816,768 priority Critical patent/US20050250936A1/en
Publication of US20050250936A1 publication Critical patent/US20050250936A1/en
Priority to US11/715,679 priority patent/US8518411B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the invention relates to recombinant proteins having improved refolding properties, improved physical properties (such as solubility and stability), improved biological activity, including altered receptor binding, improved targeting capabilities, latent forms of proteins, and methods for producing such proteins. More particularly, the invention relates to biosynthetic members of the TGF- ⁇ super-family of structurally-related proteins.
  • modified protein constructs include TGF- ⁇ family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers.
  • the TGF- ⁇ superfamily includes five distinct forms of TGF- ⁇ (Sporn and Roberts (1990) in Peptide Growth Factors and Their Receptors , Sporn and Roberts, eds., Springer-Verlag: Berlin pp. 419-472), as well as the differentiation factors vg-1 (Weeks and Melton (1987) Cell 51: 861-867), DPP-C polypeptide (Padgett et al. (1987) Nature 325: 81-84), the hormones activin and inhibin (Mason et al. (1985) Nature 318: 659-663; Mason et al.
  • the proteins of the TGF- ⁇ superfamily are disulfide-linked homo- or heterodimers that are expressed as large precursor polypeptide chains containing a hydrophobic signal sequence, a long and relatively poorly conserved N-terminal pro region sequence of several hundred amino acids, a cleavage site, and a mature domain comprising an N-terminal region that varies among the family members and a more highly conserved C-terminal region.
  • This C-terminal region present in the processed mature proteins of all known family members, contains approximately 100 amino acids with a characteristic cysteine motif having a conserved six or seven cysteine skeleton.
  • TGF- ⁇ 1 has been cloned (Derynck et al. (1985) Nature 316: 701-705), and expressed in Chinese hamster ovary cells (Gentry et al. (1987) Mol. Cell. Biol. 7: 3418-3427). Additionally, recombinant human TGF- ⁇ 2 (deMartin et al. (1987) EMBO J. 6: 3673), as well as human and porcine TGF- ⁇ 3 (Derynck et al. (1988) EMBO J. 7: 3737-3743; Dijke et al. (1988) Proc. Natl. Acad. Sci. USA 85: 4715), have been cloned.
  • TGF- ⁇ and the polypeptides of the inhibin/activin group appear to play a role in the regulation of cell growth and differentiation.
  • MIS causes regression of the Mullerian duct in development of the mammalian male embryo
  • dpp the gene product of the Drosophila decapentaplegic complex
  • Vg-1 is involved in mesoderm induction in Xenopus
  • Vgr-1 has been identified in a variety of developing murine tissues.
  • OP-1 BMP-7
  • other osteogenic proteins have been produced using recombinant techniques (U.S. Pat. No. 5,011,691 and PCT Application No. US 90/05903) and shown to be able to induce formation of true endochondral bone in vivo.
  • BMP-2 has been recombinantly produced in monkey COS-1 cells and Chinese hamster ovary cells (Wang et al. (1990) Proc. Natl. Acad. Sci. USA 87: 2220-2224).
  • the family of proteins taught as having osteogenic activity as judged by the Sampath and Reddi bone formation assay have been shown to be morphogenic, i.e., capable of inducing the developmental cascade of tissue morphogenesis in a mature mammal (See PCT Application No. US 92/01968).
  • these proteins are capable of inducing the proliferation of uncommitted progenitor cells, and inducing the differentiation of these stimulated progenitor cells in a tissue-specific manner under appropriate environmental conditions.
  • the morphogens are capable of supporting the growth and maintenance of these differentiated cells.
  • morphogenic activities allow the proteins to initiate and maintain the developmental cascade of tissue morphogenesis in an appropriate, morphogenically permissive environment, stimulating stem cells to proliferate and differentiate in a tissue-specific manner, and inducing the progression of events that culminate in new tissue formation. These morphogenic activities also allow the proteins to induce the “redifferentiation” of cells previously stimulated to stray from their differentiation path. Under appropriate environmental conditions it is anticipated that these morphogens also may stimulate the “redifferentiation” of committed cells.
  • the osteogenic proteins generally are classified in the art as a subgroup of the TGF- ⁇ superfamily of growth factors (Hogan (1996), Genes & Development, 10:1580-1594), and are variously termed “osteogenic proteins”, “morphogenic proteins”, “morphogens”, “bone morphogenic proteins” or “BMPs” are identified by their ability to induce ectopic, endochondral bone morphogenesis.
  • OP-1 also known as BMP-7, and the Drosophila homolog 60A
  • osteogenic protein-2 also known as BMP-8
  • osteogenic protein-3 also known as BMP-2A or CBMP-2A, and the Drosophila homolog DPP
  • BMP-3 also known as BMP-4
  • BMP-5 also known as BMP-6 and its murine homolog Vgr-1, BMP-9, BMP-10, BMP-11, BMP-12, GDF3 (also known as Vgr2), GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, BMP-13, BMP-14, BMP-15, GDF-5 (also known as CDMP-1 or MP52), GDF-6 (also known as CDMP-2 or BMP-13), GDF-7 (also known as CDMP-3 or BMP-12), the Xenopus homolog Vg1 and NODAL, UNIV
  • osteogenic proteins can induce recruitment and/or stimulation of progenitor cells, thereby inducing their differentiation into chondrocytes and osteoblasts, and further inducing differentiation of intermediate cartilage, vascularization, bone formation, remodeling, and, finally, marrow differentiation.
  • these osteogenic proteins when admixed with either naturally-sourced matrix materials such as collagen or synthetically-prepared polymeric matrix materials, to induce bone formation, including membraneous and endochondral bone formation, under conditions where true replacement bone would not otherwise occur.
  • these osteogenic proteins when combined with a matrix material, these osteogenic proteins induce formation of new bone in large segmental bone defects, spinal fusions, clavarial defects, and fractures.
  • Prokaryotic systems such as E. coli are useful for producing commercial quantities of proteins, as well as for evaluating biological properties of naturally occurring or biosynthetic mutants and analogs.
  • an over-expressed eukaryotic protein aggregates as an insoluble intracellular precipitate (“inclusion body”) in the prokaryote host cell.
  • the aggregated protein is then collected from the inclusion bodies, solubilized using one or more standard denaturing agents, and then allowed, or induced, to refold into a functional state. Proper refolding to form a biologically active protein structure requires proper formation of any disulfide bonds.
  • TGF- ⁇ 2 and OP-1 have been determined. Although TGF- ⁇ 2 and OP-1 exhibit only about 35% amino acid identity in their respective amino acid sequences the tertiary and quaternary structures of both molecules are strikingly similar. Both TGF- ⁇ 2 and OP-1 are dimeric in nature and have a unique folding pattern involving six of the seven C-terminal cysteine residues, as illustrated in FIG. 1A .
  • FIG. 1A shows that in each subunit four cysteines bond to generate an eight residue ring, and two additional cysteine residues form a disulfide bond that passes through the ring to form a knot-like structure.
  • the TGF- ⁇ 2 and OP-1 monomer subunits comprise three major structural elements and an N-terminal region.
  • the structural elements are made up of regions of contiguous polypeptide chain that possess over 50% secondary structure of the following types: (1) loop, (2) ⁇ -helix and (3) ⁇ -sheet. Furthermore, in these regions the N-terminal and C-terminal strands are not more than 7 A° apart.
  • the residues between the 1st and 2nd conserved cysteines form a structural region characterized by an anti-parallel ⁇ -sheet finger, referred to herein as the finger 1 region (F1).
  • a ribbon trace of the finger 1 peptide backbone is shown in FIG. 1B .
  • FIG. 1D A ribbon trace of the finger 2 peptide backbone is shown in FIG. 1D .
  • a ⁇ -sheet finger is a single amino acid chain, comprising a ⁇ -strand that folds back on itself by means of a ⁇ -turn or some larger loop so that the entering and exiting strands form one or more anti-parallel ⁇ -sheet structures.
  • the third major structural region, involving the residues between the 3rd and 4th conserved cysteines in FIG. 1A is characterized by a three turn ⁇ -helix referred to herein as the heel region (H).
  • a ribbon trace of the heel peptide backbone is shown in FIG. 1C .
  • the organization of the monomer structure is similar to that of a left hand where the knot region is located at the position equivalent to the palm, finger 1 is equivalent to the index and middle fingers, the ⁇ -helix is equivalent to the heel of the hand, and finger 2 is equivalent to the ring and small fingers.
  • the N-terminal region (not well defined in the published structures) is predicted to be located at a position roughly equivalent to the thumb.
  • the subunits are oriented such that the heel region of one subunit contacts the finger regions of the other subunit with the knot regions of the connected subunits forming the core of the molecule.
  • the 4th cysteine forms a disulfide bridge with its counterpart on the second chain thereby equivalently linking the chains at the center of the palms.
  • the dimer thus formed is an ellipsoidal (cigar shaped) molecule when viewed from the top looking down the two-fold axis of symmetry between the subunits ( FIG. 2A ). Viewed from the side, the molecule resembles a bent “cigar” since the two subunits are oriented at a slight angle relative to each other ( FIG. 2B ).
  • TBF- ⁇ family members including BMPs, fall into the category of poor refolder proteins. While some members of the TBF- ⁇ protein family can be folded efficiently in vitro as, for example, when produced in E. coli or other prokaryotic hosts, many others, including BMP5, BMP6, and BMP7, cannot. See, e.g., EP 0433225, U.S. Pat. No. 5,399,677, U.S. Pat. No. 5,756,308 and U.S. Pat. No. 5,804,416.
  • the present invention provides modified TGF- ⁇ family proteins which comprise N-terminal extensions, truncations and other modifications at the N-terminal end of C-terminal active domains.
  • Modified proteins of the invention have altered refolding properties and altered solubility with respect to naturally occurring proteins when expressed recombinantly.
  • Modified proteins of the invention also have altered activity profiles, including enhanced specific activity, and are amenable to tissue-specific targeting or specific surface binding.
  • the invention provides “mutant” forms of proteins that improve the refolding properties of “poor refolder” TGF- ⁇ family members.
  • a “poor refolder” protein means any protein that, when induced to refold under suitable refolding conditions, yields less than about 1% properly refolded material, as measured using a standard protocol (see below).
  • suitable refolding conditions are conditions under which proteins can be refolded to the extent required to confer functionality.
  • Structural parameters relevant to the compositions and methods of the instant invention include one or more disulfide bridges properly distributed throughout the dimeric protein's structure and which require a reduction-oxidation (“redox”) reaction step to yield a folded structure.
  • Redox reactions typically occur at neutral pH, i.e., in the range of about pH 7.0-8.5, typically in the range of about pH 7.5-8.5, and preferably under physiologically-compatible conditions. The skilled artisan will appreciate and recognize optimal conditions for success.
  • the proteins preferably are manufactured in accordance with the principles disclosed herein by assembly of nucleotides and/or joining DNA restriction fragments to produce synthetic DNAs.
  • the DNAs are transfected into an appropriate protein expression vehicle, the encoded protein expressed, folded if necessary, and purified. Particular constructs can be tested for activity in vitro.
  • the tertiary structure of the candidate protein constructs may be iteratively refined and binding modulated by site-directed or nucleotide sequence directed mutagenesis aided by the principles disclosed herein, computer-based protein structure modeling, and recently developed rational drug design techniques to improve or modulate specific properties of a molecule of interest.
  • Known phage display or other nucleotide expression systems may be exploited to produce simultaneously a large number of candidate constructs.
  • the pool of candidate constructs subsequently may be screened for binding specificity using, for example, a chromatography column comprising surface immobilized receptors, salt gradient elution to select for, and to concentrate high binding candidates, and in vitro assays.
  • Identification of a useful recombinant protein is followed by production of cell lines expressing commercially useful quantities of the protein for laboratory use and ultimately for producing therapeutically useful drugs. It has now been discovered how to design, make, test and use chimeric proteins comprising an amino acid sequence which, when properly folded, assume a tertiary structure defining a finger 1 region, a finger 2 region, and a heel region.
  • All of the constructs of the invention comprise regions of amino acid sequences defining the regions required for utility, namely, finger 1, finger 2, and heel regions, and an additional region that can modify activity, namely the N-terminal peptide sequence.
  • Sequences for the finger and heel regions may be copied from the respective finger and heel region sequences of any known TGF- ⁇ superfamily member identified herein.
  • the finger and heel regions may be selected from the amino acid sequence of a new member of this superfamily discovered hereafter using the principles disclosed hereinbelow.
  • the finger and heel sequences also may be altered by amino acid substitution, for example by exploiting substitute amino acid residues selected in accordance with the principles disclosed in Smith et al. (1990) Proc. Natl. Acad. Sci. USA 87: 118-122, the disclosure of which is incorporated herein by reference.
  • Smith et al. disclose an amino acid class hierarchy, similar to the amino acid hierarchy table set forth in FIG. 3 , which may be used to rationally substitute one amino acid for another while minimizing gross conformational distortions of the type which otherwise may inactivate the protein.
  • many synthetic finger 1, finger 2, and heel region sequences having only 70% homology with natural regions, preferably 80%, and most preferably at least 90%, may be used to produce active morphon constructs. It is contemplated also, as disclosed herein, that the size of the constructs may be reduced significantly by truncating the natural finger and heel regions of the template TGF- ⁇ superfamily member.
  • amino acid residues are understood to include any amino acid residue, naturally-occurring or synthetic, that typically carries a negative charge on its R group under physiological conditions. Examples include, without limitation, aspartic acid (“Asp”) and glutamic acid (“Glu”). Similarly, basic or positively charged residues include any amino acid residue, naturally-occurring or synthetically created, that typically carries a positive charge on its R group under physiological conditions. Examples include, without limitation, arginine (“Arg”), lysine (“Lys”) and histidine (“His”).
  • hydrophilic residues include both acidic and basic amino acid residues, as well as uncharged residues carrying amide groups on their R groups, including, without limitation, glutamine (“Gln”) and asparagine (“Asn”), and polar residues carrying hydroxyl groups on their R groups, including, without limitation, serine (“Ser”), tyrosine (“Tyr”) and threonine (“Thr”).
  • Gln glutamine
  • Asn asparagine
  • polar residues carrying hydroxyl groups on their R groups including, without limitation, serine (“Ser”), tyrosine (“Tyr”) and threonine (“Thr”).
  • biosynthesis or “biosynthetic” means occurring as a result of, or originating from a ligation of naturally-or synthetically-derived fragments. For example, but not limited to, ligating peptide or nucleic acid fragments corresponding to one or more subdomains (or fragments thereof) disclosed herein. “Chemosynthesis” or “chemosynthetic” means occurring as a result of, or originating from, a chemical means of production. For example, but not limited to, synthesis of a peptide or nucleic acid sequence using a standard automated synthesizer/sequencer from a commercially-available source.
  • “Recombinant” production or technology means occurring as a result of, or originating from, a genetically engineered means of production. For example, but not limited to, expression of a genetically-engineered DNA sequence or gene encoding a chimeric protein (or fragment thereof) of the present invention. Also included within the meaning of the foregoing are the teachings set forth below in at least Sections I.B.; Section II; and at least Examples 1 and 2. “Synthetic” means occurring or originating non-naturally, i.e., not naturally occurring.
  • corresponding residue position refers to a residue position in a protein sequence that corresponds to a given position in an OP-1 or other reference TGF- ⁇ family member amino acid sequence, when the two sequences are aligned.
  • sequences of BMP family members are highly conserved in the C-terminal active domain, and particularly in the finger 2 sub-domain.
  • Amino acid sequence alignment methods and programs are well developed in the art. See, e.g., the method of Needleman, et al. (1970) J. Mol. Biol. 48:443-453, implemented conveniently by computer programs such as the Align program (DNAstar, Inc.).
  • hOP-1 human OP-1, also referred to in the art as “BMP-7”
  • BMP-7 bone OP-1
  • TGF- ⁇ family member or “TGF- ⁇ family protein,” means a protein known to those of ordinary skill in the art as a member of the TGF- ⁇ superfamily. Structurally, such proteins are disulfide-linked homo or heterodimers that are expressed as large precursor polypeptide chains containing a hydrophobic signal sequence, an N-terminal pro region of several hundred amino acids, and a mature domain comprising a variable N-terminal region and a more highly conserved C-terminal region containing approximately 100 amino acids with a characteristic cysteine motif having a conserved six or seven cysteine skeleton. These structurally-related proteins have been identified as being involved in a variety of developmental events.
  • TGF- ⁇ family members are typified by TGF ⁇ 1 and OP-1.
  • Other TGF- ⁇ family proteins useful in the practice of the present invention include osteogenic proteins (as defined below), vg-1, DPP-C polypeptide, the hormones activin and inhibin, MIS, VGR-1 and growth/differentiation factors GDF-1, GDF-3, GDF-9 and dorsalin-1.
  • Type I and Type II receptors are both serine/threonine kinases and share similar structures: an intracellular domain that consists essentially of the kinase, and a short, extended hydrophobic sequence sufficient to span the membrane one time, and an extracellular ligand-binding domain characterized by a high concentration of conserved cysteines.
  • the various Type I and Type II receptors have specific binding affinity with OP-1 and other morphogenic proteins, and their analogs, including the modified morphogens of the present invention.
  • Osteogenic protein or “bone morphogenic protein,” means a TGF- ⁇ superfamily protein which can induce the full cascade of morphogenic events culminating in skeletal tissue formation, including but not limited to cartilage and/or endochondral bone formation.
  • Osteogenic proteins useful herein include any known naturally-occurring native proteins including allelic, phylogenetic counterpart and other variants thereof, whether naturally-occurring or biosynthetically produced (e.g., including “muteins” or “mutant proteins”), as well as new, osteogenically active members of the general morphogenic family of proteins. As described herein, this class of proteins is generally typified by human osteogenic protein 1 (hOP-1).
  • osteogenic proteins useful in the practice of the invention include osteogenically active forms of proteins included within the list of: OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-9, DPP, Vg-1, Vgr, 60A protein, CDMP-1, CDMP-2, CDMP-3, GDF-1, GDF-3, GDF-5, 6, 7, MP-52, BMP-10, BMP-11, BMP-12, BMP-13, BMP-15, UNIVIN, NODAL, SCREW, ADMP or NEURAL, including amino acid sequence variants thereof, and/or heterodimers thereof.
  • osteogenic protein useful in the practice of the invention includes any one of: OP-1, BMP-2, BMP4, BMP-12, BMP-13, GDF-5, GDF-6, GDF-7, CDMP-1, CDMP-2, CDMP-3, MP-52 and amino acid sequence variants and homologs thereof, including species homologs thereof.
  • useful osteogenically active proteins have polypeptide chains with amino acid sequences comprising a sequence encoded by a nucleic acid that hybridizes, under low, medium or high stringency hybridization conditions, to DNA or RNA encoding reference osteogenic sequences, e.g., C-terminal sequences defining the conserved seven cysteine domains of OP-1, OP-2, BMP-2, BMP-4, BMP-5, BMP-6, 60A, GDF-5, GDF-6, GDF-7 and the like.
  • high stringent hybridization conditions are defined as hybridization according to known techniques in 40% formamide, 5 ⁇ SSPE, 5 ⁇ Denhardt's Solution, and 0.1% SDS at 37° C.
  • FIG. 4 lists the C-terminal 35 residues defining the finger 2 subdomain of various known members of the TGF- ⁇ superfamily. Any one of the proteins on the list that is a poor refolder can be improved by the methods of the invention, as can other known or discoverable family members.
  • the biologically active osteogenic proteins suitable for use with the present invention can be identified by means of routine experimentation using the art-recognized bioassay described by Reddi and Sampath. A detailed description of useful proteins follows. Equivalents can be identified by the artisan using no more than routine experimentation and ordinary skill.
  • Morphogens or “morphogenic proteins” as contemplated herein includes members of the TGF- ⁇ superfamily which have been recognized to be morphogenic, i.e., capable of inducing the developmental cascade of tissue morphogenesis in a mature mammal (See PCT Application No. US 92/01968).
  • these morphogens are capable of inducing the proliferation of uncommitted progenitor cells, and inducing the differentiation of these stimulated progenitor cells in a tissue-specific manner under appropriate environmental conditions.
  • the morphogens are capable of supporting the growth and maintenance of these differentiated cells.
  • morphogenic activities allow the proteins to initiate and maintain the developmental cascade of tissue morphogenesis in an appropriate, morphogenically permissive environment, stimulating stem cells to proliferate and differentiate in a tissue-specific manner, and inducing the progression of events that culminate in new tissue formation.
  • These morphogenic activities also allow the proteins to induce the “redifferentiation” of cells previously stimulated to stray from their differentiation path. Under appropriate environmental conditions it is anticipated that these morphogens also may stimulate the “redifferentiation” of committed cells.
  • described herein are numerous means for testing morphogenic proteins in a variety of tissues and for a variety of attributes typical of morphogenic proteins. It will be understood that these teachings can be used to assess morphogenic attributes of native proteins as well as modified proteins of the present invention.
  • Useful native or parent proteins of the present invention also include those sharing at least 70% amino acid sequence homology within the C-terminal seven-cysteine domain of human OP-1.
  • the first step for performing an alignment is to use an alignment tool, such as the dynamic programming algorithm described in Needleman et al., J. M OL . B IOL. 48: 443 (1970); the teachings of which are incorporated by reference herein and the Align Program, a commercial software package produced by DNAstar, Inc. After the initial alignment is made, it is then refined by comparison to a multiple sequence alignment of a family of related proteins.
  • a percent homology score is calculated.
  • the individual amino acids of each sequence are compared sequentially according to their similarity to each other. Similarity factors include similar size, shape and electrical charge.
  • One particularly preferred method of determining amino acid similarities is the PAM250 matrix described in Dayhoff et al., 5 A TLAS OF P ROTEIN S EQUENCE AND S TRUCTURE 345-352 (1978 & Supp.), incorporated by reference herein.
  • a similarity score is first calculated as the sum of the aligned pairwise amino acid similarity scores. Insertions and deletions are ignored for the purposes of percent homology and identity. Accordingly, gap penalties are not used in this calculation.
  • the raw score is then normalized by dividing it by the geometric mean of the scores of the candidate compound and the seven cysteine domain. The geometric mean is the square root of the product of these scores. The normalized raw score is the percent homology.
  • conservative substitutions are residues that are physically or functionally similar to the corresponding reference residues, e.g., that have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Particularly preferred conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al. Ibid.
  • conservative substitutions include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups are well-known: (a) glycine, alanine; (b) valine, isoleucine, leucine; (c) aspartic acid, glutamic acid; (d) asparagine, glutamine; (e) serine, threonine; (f) lysine, arginine, histidine; and (g) phenylalanine, tyrosine.
  • groups are well-known: (a) glycine, alanine; (b) valine, isoleucine, leucine; (c) aspartic acid, glutamic acid; (d) asparagine, glutamine; (e) serine, threonine; (f) lysine, arginine, histidine; and (g) phenylalanine, tyrosine.
  • “conservative variant” or “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid in a given polypeptide chain, provided that antibodies having binding specificity for the resulting substituted polypeptide chain also have binding specificity (i.e., “crossreact” or “immunoreact” with) the unsubstituted or parent polypeptide chain.
  • a “conserved residue position” refers to a location in a reference amino acid sequence occupied by the same amino acid or a conservative variant thereof in at least one other member sequence. For example, in FIG. 4 , comparing BMP-2, BMP-4, BMP-5, and BMP-6 with OP-1 as the reference sequence, positions 1, 5, 9, 12, 14, 15, 16, 17, 19, 22, etc. are conserved positions, and residues 2, 3, 4, 6, 7, 8, 10, 11, 13, 18, 20, 21, etc. are non-conserved positions.
  • the “base” or “neck” region of the finger 2 sub-domain is defined by residues 1-10 and 22-35, as exemplified by OP-1, and counting from the first residue following the cysteine doublet in the C-terminal active domain. (See FIG. 4 ).
  • the corresponding base or neck region for a longer protein, such as BMP-9 or Dorsalin is defined by residues 1-10 and 23-36; for a shorter protein, such as NODAL, the corresponding region is defined by residues 1-10 and 22-34 (See FIG. 4 ).
  • residues corresponding to the base or neck region of the finger 2 subdomain are residues 397-406 (corresponding to residues 1-10 in FIG. 4 ) and residues 418-431 (corresponding to residues 22-35 in FIG. 4 ).
  • C-terminal active domain refers to the conserved C-terminal region of mature TGF- ⁇ family proteins.
  • the C-terminal active domain contains approximately 100 amino acids with a characteristic cysteine motif having a six or seven cysteine skeleton.
  • the cysteine pattern of the C-terminus of all of the proteins is in the identical format ending in the sequence Cys-X-Cys-X (Sporn and Roberts (1990), supra.)
  • amino acid sequence homology includes both amino acid sequence identity and similarity. Homologous sequences share identical and/or similar amino acid residues, where similar residues are conservative substitutions for, or “allowed point mutations” of, corresponding amino acid residues in an aligned reference sequence.
  • chimeric protein refers to any BMP or TGF- ⁇ family member synthetic construct wherein the amino acid sequence of at least one defined region, domain or sub-domain, such as the finger 1, finger 2 or heel sub-domain, has been replaced in whole or in part with an amino acid sequence from at least one other, different BMP or TGF- ⁇ family member protein, such that the resulting construct has an amino acid sequence recognizable as being derived from the different protein sources.
  • Chimeric constructs also comprise recombinant fusion proteins in which the C-terminal active domain of one morphogen is fused to the N-terminal domain of another morphogen.
  • leader sequence is any sequence of amino acids corresponding to a sequence of nucleotides upstream, that is, positioned farther to the C-terminal end, of the C-terminal active domain region of a TGF- ⁇ family protein. Modifications in the leader sequence can alter refolding properties, activity levels, solubility, control activation, and promote tissue-targeting as well as affinity-binding ability.
  • useful expression host cells include prokaryotes and eukaryotes, including any host cell capable of making an inclusion body.
  • Particularly useful host cells include, without limitation, bacterial hosts such as E. coli , as well as B. subtilis and Pseudomonas .
  • Other useful hosts include lower eukaryotes, such as Saccharomyces cereviceae or other yeast, and higher eukaryotes, such as Drosophila , CHO cells, and other mammalian cells, and the like.
  • chemical synthesis methods can also be utilized to generate the modified proteins of the present invention.
  • the invention provides construction of recombinant proteins not readily expressed in mammalian cells, such as, for example, fusion proteins and the like.
  • a recombinant gene encoding a fusion protein having bone targeting properties is constructed, wherein a single sequence encodes both a BMP and an antibody binding site having specificity for a bone matrix protein such as osteocalcin or fibronectin.
  • a fusion protein can also be constructed to bind to cell surface receptors such as those on osteoprogenitor cells or chondrocytes.
  • Other recombinant genes may encode for fusion proteins that specifically bind metals or other proteins. The specificity of the binding would depend on the composition of the leader sequence that is added to the BMP. These genes can be expressed in E. coli and refolded in vitro.
  • a cleavable fusion construct (cleavable by proteases—such as trypsin, V8, factor Xa and others, or chemically—with mild acid, hydroxylamine and other agents) is synthesized wherein the TGF- ⁇ protein is attached to a leader sequence that blocks activity.
  • the activity of a TGF- ⁇ family member is restored or enhanced by cleaving a portion or all of the leader sequence.
  • the leader sequence is also a tissue-targeting sequence, such that release can be controlled to occur at the target site in vivo.
  • the construction of the cleavage site can also allow one to control the release of active protein.
  • a cleavable “hexa-his”, FB leader, or collagen binding sequence described below may be a suitable leader sequence for a latent form of the protein.
  • the tissue-targeting domain can be separated from a BMP by a leader sequence that includes a run of at least three basic residues, which is known to be cleaved in vivo.
  • the leader sequence can be constructed so that the portion of the protein that is inhibiting specific activity is cleaved and activity restored, but the tissue-targeting portion of the protein is retained.
  • the leader sequence of the TGF- ⁇ family protein is replaced by a leader sequence of another TGF- ⁇ member.
  • the resultant “chimeric” protein may have altered solubility, folding and/or tissue targeting activity, improved stability, and/or the ability to bind to specific surfaces.
  • the fusion proteins are combined with other TGF- ⁇ family proteins to form heterodimers, wherein one can exploit the properties of each protein.
  • a fusion protein with tissue-targeting properties but no activity forms a heterodimer with a different protein which has activity, but no tissue-targeting ability.
  • the former protein delivers the heterodimer to a target site where the latter protein can perform its function.
  • the invention provides biosynthetic BMPs and TGF- ⁇ family member proteins having improved refolding properties under neutral or physiological conditions.
  • the biosynthetic proteins of the invention have improved refolding properties at a pH in the range of about 5.0-10.0, preferably in the range of about 6.0-9.0, more preferably in the range of about 6.0-8.5, including in the range of about pH 7.0-7.5.
  • the invention provides biosynthetic BMPs and TGF- ⁇ family member proteins having improved solubility properties under neutral or physiological conditions.
  • the biosynthetic proteins of the invention have improved solubility at a pH in the range of about 5.0-10.0, preferably in the range of about 6.0-9.0, more preferably in the range of about 6.0-8.5, including in the range of about pH 7.0-7.5.
  • the invention provides biologically active biosynthetic BMPs and TGF- ⁇ family member constructs competent to refold under physiological conditions and having altered isoelectric points as compared with the parent sequence.
  • the invention provides a method for folding homodimers and heterodimers, which are poor refolders, under physiological or neutral pH conditions.
  • the method comprises the steps of providing one or more solubilized TGF- ⁇ family protein constructs of the invention, exposing the solubilized protein to a redox reaction in a suitable refolding buffer, and allowing the protein subunits to refold into homodimers and/or heterodimers, as desired.
  • the modified TGF- ⁇ family proteins of the invention are not denatured prior to exposing them to the redox reaction.
  • the redox reaction system can utilize oxidized and reduced forms of glutathione, DTT, ⁇ -mercaptomethanol, cysteine and cystamine.
  • the redox reaction system relies on air oxidation, preferably in the presence of a metal catalyst, such as copper.
  • these can be used as redox systems at ratios of reductant to oxidant of about 1:10 to about 10:1, preferably in the range of about 1:2 to 2:1.
  • the protein is solubilized in the presence of a detergent, including an ionic detergent, a non-ionic detergent, e.g.
  • the refolding reaction occurs in a pH range of about 5.0-10.0, preferably in the range of about 6.0-9.0, more preferably in the range of about 7.0-8.5. In still another embodiment, the refolding reaction occurs at a temperature within the range of about 32-0° C., preferably in the range of about 25-4° C. Where heterodimers are being created, optimal ratios for adding the two different subunits readily can be determined empirically and without undue experimentation.
  • the invention provides methods for recombinantly producing poor refolder BMP and other TGF- ⁇ family member proteins in a host cell, including a bacterial host, or any other host cell where overexpressed protein aggregates in a form that requires solubilization and/or refolding in vitro.
  • the method comprises the steps of providing a host cell transfected with nucleic acid molecules encoding one or more of the biosynthetic proteins of the invention, cultivating the host cells under conditions suitable for expressing the biosynthetic protein, collecting the aggregated protein, and solubilizing and refolding the protein using the steps outlined above.
  • the method comprises the additional step of transfecting the host cell with a nucleic acid encoding the biosynthetic protein of the invention.
  • Modified morphogens of the invention may be used to form bone and/or cartilage in conjunction with a biocompatible matrix such as (but not limited to) collagen, hydroxyapatite, ceramics, carboxymethylcellulose, and/or other carrier suitable or matrix material.
  • a biocompatible matrix such as (but not limited to) collagen, hydroxyapatite, ceramics, carboxymethylcellulose, and/or other carrier suitable or matrix material.
  • Such combinations are particularly useful in methods for regenerating bone, cartilage and/or other non-mineralized skeletal or connective tissues such as (but not limited to) articular cartilage, fibrocartilage, ligament, tendon, joint capsule, menisci, intervertebral disks, synovial membrane tissue, muscle, and fascia, to name but a few. See e.g. U.S. Pat. Nos. 5,674,292, 5,840,325 and U.S. application Ser. No.
  • the present invention contemplates that the binding and/or adherence properties to such matrix materials can be altered using the techniques disclosed herein for generating protein constructs.
  • the modified proteins of the invention may also be utilized to generate tendon, ligament and/or muscle tissue.
  • FIG. 1A is a simplified line drawing useful in describing the structure of a monomeric subunit of a TGF- ⁇ superfamily member. See the Background of the Invention, supra, for explanation.
  • FIGS. 1B, 1C , and 1 D are monovision ribbon tracings of the respective peptide backbones of typical secondary structures of the finger 1, heel, and finger 2 regions.
  • FIGS. 2A and 2B are stereo peptide backbone ribbon trace drawings illustrating the generic three-dimensional shape of TGF- ⁇ superfamily member protein dimer: A) from the “top” (down the two-fold axis of symmetry between the subunits) with the axes of the helical heel regions generally normal to the paper and the axes of each of the finger 1 and finger 2 regions generally vertical, and B) from the “side” with the two-fold axis between the subunits in the plane of the paper, with the axes of the heels generally horizontal, and the axes of the fingers generally vertical.
  • the reader is encouraged to view the stereo alpha carbon trace drawings in wall eyed stereo to understand better the spatial relationships in the morphon design.
  • FIG. 3 is a pattern definition table prepared in accordance with the teaching of Smith and Smith (1990) Proc. Natl. Acad. Sci. USA 87:118-122.
  • FIG. 4 lists the aligned C-terminal residues defining the finger 2 sub-domain for various known members of the BMP family, and TGF- ⁇ superfamily of proteins, starting with the first residue following the cysteine doublet.
  • FIGS. 5A, 5B , and 5 C are single letter code listings of amino acid sequences, arranged to indicate alignments and homologies of the finger 1, heel, and finger 2 regions, respectively, of the currently known members of the TGF- ⁇ superfamily. Shown are the respective amino acids comprising each region of human TGF- ⁇ 1 through TGF- ⁇ 5 (the TGF- ⁇ subgroup), the Vg/dpp subgroup consisting of dpp, Vg-1, Vgr-1, 60A (see copending U.S. Ser. No.
  • BMP-2A also known in the literature as BMP-2
  • dorsalin BMP-2B
  • BMP-3 also known in the literature as BMP-5
  • BMP-6 also known in the literature as BMP-6
  • OP-1 also known in the literature as BMP-7
  • OP-2 see PCT/US91/07635 and U.S. Pat. No. 5,266,683
  • OP-3 U.S. Ser. No. 07/971,091
  • GDF subgroup consisting of GDF-1, GDF-3, and GDF-9
  • Inhibin subgroup consisting of Inhibin ⁇ , Inhibin ⁇ A, and Inhibin ⁇ B.
  • the dashes (-) indicate a peptide bond between adjacent amino acids.
  • a consensus sequence pattern for each subgroup is shown at the bottom of each subgroup.
  • FIG. 6 is a single letter code listing of amino acid sequences, identified in capital letter in standard single letter amino acid code, and in lower case letters to identify groups of amino acids useful in that location, wherein the lower case letters stand for the amino acids indicated in accordance with the pattern definition key table set forth in FIG. 3 .
  • FIG. 6 identifies preferred pattern sequences for constituting the finger 1, heel, and finger 2 regions of biosynthetic constructs of the invention.
  • the dashes (-) indicate a peptide bond between adjacent amino acids.
  • FIG. 7 (A) shows the nucleotide and corresponding amino acid sequences of H2487, a modified OP-1 comprising N-terminal decapeptide collagen binding site inserted upstream of the seven-cysteine domain.
  • FIG. 7 (B) shows the nucleotide and corresponding amino acid sequences of H2440, a modified OP-1 comprising a hexa-histidine domain attached 35 residues upstream of the first cysteine in the seven-cysteine domain.
  • FIG. 7 (C) shows the nucleotide and amino acid sequences of H2521, a modified OP-1 comprising an FB leader domain of protein A attached 15 residues upstream of the first cysteine in the seven-cysteine domain.
  • FIG. 7 (D) shows the nucleotide and amino acid sequences of H2525, a modified OP-1 comprising both an FB leader domain of protein A and a hexa-histidine domain.
  • FIG. 7 (E) shows the nucleotide and amino acid sequences of H2527, a modified OP-1 comprising an FB leader domain, a hexa-histidine domain, and an ASP-PRO acid cleavage site.
  • FIG. 7 (F) shows the nucleotide and amino acid sequences of H2528, a modified CDMP-3 comprising an FB leader domain and a hexa-histidine domain.
  • FIG. 7 (G) shows the nucleotide and amino acid sequences of H2469, a modified OP-1 (truncated) comprising 14 original residues upstream of the first cysteine in the conserved seven-cysteine domain.
  • FIG. 7 (H) shows the nucleotide and amino acid sequences of H2510, a modified OP-1 comprising a collagen binding site inserted 7 residues upstream of the first cysteine in the conserved seven-cysteine domain.
  • FIG. 7 (I) shows the nucleotide and amino acid sequences of H2523, a modified OP-1 comprising a collagen peptide and a spacer added 13 residues upstream from the first cysteine in the conserved seven-cysteine domain.
  • FIG. 7 (J) shows the nucleotide and amino acid sequences of H2524, a modified OP-1 comprising a hexa-histideine domain, a collagen peptide and a spacer added 13 residues upstream from the first cysteine in the conserved seven-cysteine domain.
  • FIG. 8 is a restriction map encoding the OP-1 C-terminal seven cysteine active domain
  • FIG. 9 (A) is a schematic representation of various biosynthetic chimeric BMP constructs
  • FIG. 9 (B) is a schematic representation of biosynthetic BMP mutants and their refolding and ROS activity
  • FIG. 10 shows the number of charged residues in the C-terminal sub-domains for various BMPs.
  • FIG. 11 is a graph of ROS activity for OP-1 (standard), the mutant H2549 protein and H2549 treated with trypsin, plotted as concentration (ng/mL) vs. optical density (at 405 nm).
  • FIG. 12 is a graph of ROS activity for OP-1 (standard) and various fractions of the mutant H2223 protein and the trypsin truncated form of this protein, plotted as concentration (ng/mL) vs. optical density (at 405 nm).
  • FIG. 13 (A) is a graph of ROS activity for OP-1 homodimer (from CHO cells), BMP-2 homodimer and hexa-his OP-1 heterodimer, plotted as concentration (ng/mL) vs. optical density (405 nm).
  • FIG. 13 (B) is a graph of ROS activity for OP-1 homodimer (from CHO cells), hexa-his OP-1/BMP-2 heterodimer and hexa-his OP-1, plotted as concentration (ng/mL) vs. optical density (405 nm).
  • FIG. 14 is a graph of ROS activity for OP-1 (standard), BMP-2 mutant H2142 protein homodimer, mutant H2525 protein homodimer and H2525/2142 heterodimer, plotted as concentration (ng/mL) vs. optical density (405 nm).
  • FIG. 15 shows the amino acid sequences for the finger 2 subdomain of various OP-1 mutants and their folding efficiencies and biological activities in the ROS cell based alkaline phosphotase assay.
  • Modified proteins of the invention comprise N-terminal modifications of naturally-occurring TGF- ⁇ family members, especially morphogenic proteins. These modifications include extension, truncation, and/or activation by protease or chemical cleavage at specific sites (e.g., by acid or CNBr), attachment (fusion) of distinct protein domains and production of heterodimers with subunits from other TGF- ⁇ family members.
  • modifications include extension, truncation, and/or activation by protease or chemical cleavage at specific sites (e.g., by acid or CNBr), attachment (fusion) of distinct protein domains and production of heterodimers with subunits from other TGF- ⁇ family members.
  • the detailed description provided below describes an exemplary array of substitutions, fusions, and extensions that result in improved activity and pharmaceutical properties. Methods of producing modified proteins are also taught.
  • the folding capabilities of poor refolder BMPs and other members of the TGF- ⁇ superfamily of proteins, including heterodimers and chimeras thereof are improved by fusing specific targeting and receptor-binding regions to the existing N-terminal domain of BMP or TGF- ⁇ family members, which can then be cleaved at sites within the fusion protein.
  • BMP and other TGF- ⁇ family proteins that (1) are expressed recombinantly in prokaryotic or eukaryotic cells or synthesized using polypeptide synthesizers; (2) have altered folding capabilities; (3) have altered solubility under neutral pHs, including but not limited to physiological conditions; (4) have altered isoelectric points; (5) have altered stability; (6) have altered binding or adherence properties to solid surfaces (e.g., biocompatible matrices or metals); and/or (7) have a desired, altered biological activity, such as tissue and/or receptor specificity.
  • the invention provides means for testing new candidate constructs rapidly, particularly a biological or biochemical property of the candidate.
  • the invention also provides means for rapidly mapping epitopes of antibodies, for example by making chimeric proteins with different combinations of domains. Specifically, making use of the discoveries disclosed herein, morphogen sequences which otherwise could not be expressed in a prokaryotic host such as E. coli now can be modified to allow expression in E. coli and refolding in vitro.
  • the present invention can provide mechanisms for designing quick-release, slow-release and/or timed-release formulations containing a preferred chimeric protein.
  • the present invention provides mechanisms for designing formulations engineered for environmentally-triggered release of a protein construct. That is, modified proteins can be designed to modulate delivery and facilitate release and activity under particular environmental conditions in situ, such as changes in pH, presence of a specific protease, etc. Other advantages and features will be evident from the teachings below. Moreover, making use of the discoveries disclosed herein, modified proteins having altered surface-binding/surface-adherent properties can be designed and selected.
  • Surfaces of particular significance include, but are not limited to, solid surfaces which can be naturally-occurring such as bone; or porous particulate surfaces such as collagen or other biocompatible matrices; or the fabricated surfaces of prosthetic implants, including metals.
  • virtually any surface can be assayed for differential binding of constructs.
  • the present invention embraces a diversity of functional molecules having alterations in their surface-binding/surface-adherent properties, thereby rendering such constructs useful for altered in vivo applications, including slow-release, fast-release and/or timed-release formulations.
  • stability alterations can be routinely monitored using well-known techniques of circular dichroism and other indices of stability as a function of denaturant concentration or temperature.
  • solubility it is possible to manipulate this attribute so that a modified protein is either more or less soluble under physiologically-compatible conditions and it consequently diffuses readily or remains localized, respectively, when administered in vivo.
  • biosynthetic proteins and methods useful in the practice of the invention as well as methods for using and testing these proteins; and numerous, nonlimiting examples which 1) illustrate the suitability of the biosynthetic proteins and methods described herein; and 2) provide assays with which to test and use these proteins.
  • Each of the subunits in either TGF ⁇ 2 or OP-1 have a characteristic folding pattern, illustrated schematically in FIG. 1A , that involves six of the seven C-terminal cysteine residues. Briefly, four of the cysteine residues in each subunit form two disulfide bonds which together create an eight residue ring, while two additional cysteine residues form a disulfide bond that passes through the ring to form a knot-like structure.
  • each subunit in TGF- ⁇ 2 and OP-1 comprise three major tertiary structural elements and an N-terminal region.
  • the structural elements are made up of regions of contiguous polypeptide chain that possess over 50% secondary structure of the following types: (1) loop, (2) ⁇ -helix and (3) ⁇ -sheet.
  • Another defining criterion for each structural region is that the entering (N-terminal) and exiting (C-terminal) peptide strands are fairly close together, being about 7 A apart.
  • the amino acid sequence between the 1st and 2nd conserved cysteines, as shown in FIG. 1A forms a structural region characterized by an anti-parallel ⁇ -sheet finger referred to herein as the finger 1 region.
  • the residues between the 5th and 6th conserved cysteines, as shown in FIG. 1A also form an anti-parallel ⁇ -sheet finger, referred to herein as the finger 2 region.
  • a ⁇ -sheet finger is a single amino acid chain, comprising a ⁇ -strand that folds back on itself by means of a ⁇ -turn or some larger loop so that the polypeptide chain entering and exiting the region form one or more anti-parallel ⁇ -sheet structures.
  • the third major structural region involving the residues between the 3rd and 5th conserved cysteines, as shown in FIG. 1A , is characterized by a three turn ⁇ -helix, referred to herein as the heel region.
  • the organization of the monomer structure is similar to that of a left hand where the knot region is located at the position equivalent to the palm, the finger 1 region is equivalent to the index and middle fingers, the ⁇ -helix, or heel region, is equivalent to the heel of the hand, and the finger 2 region is equivalent to the ring and small fingers.
  • the N-terminal region whose sequence is not conserved across the TGF- ⁇ superfamily, is predicted to be located at a position roughly equivalent to the thumb.
  • FIGS. 1B-1D Monovision ribbon tracings of the alpha carbon backbones of each of the three major independent structural elements of the TGF- ⁇ 2 monomer are illustrated in FIGS. 1B-1D .
  • an exemplary finger 1 region comprising the first anti-parallel ⁇ -sheet segment is shown in FIG. 1B
  • an exemplary heel region comprising the three turn ⁇ -helical segment is shown in FIG. 1C
  • an exemplary finger 2 region comprising second and third anti-parallel ⁇ -sheet segments is shown in FIG. 1D .
  • FIG. 2 shows stereo ribbon trace drawings of the peptide backbone of the conformationally active TGF- ⁇ 2 dimer complex.
  • the two monomer subunits in the dimer complex are oriented with two-fold rotational symmetry such that the heel region of one subunit contacts the finger regions of the other subunit with the knot regions of the connected subunits forming the core of the molecule.
  • the 4th cysteine forms an interchain disulfide bond with its counterpart on the second chain thereby equivalently linking the chains at the center of the palms.
  • the dimer thus formed is an ellipsoidal (cigar shaped) molecule when viewed from the top looking down the two-fold axis of symmetry between the subunits ( FIG. 2A ). Viewed from the side, the molecule resembles a bent “cigar” since the two subunits are oriented at a slight angle relative to each other ( FIG. 2B ).
  • each of the structural elements which together define the native monomer subunits of the dimer are labeled 22, 22′, 23, 23′, 24, 24′, 25, 25′, 26, and 26′, wherein, elements 22, 23, 24, 25, and 26 are defined by one subunit and elements 22′, 23′, 24′, 25′, and 26′ belong to the other subunit.
  • 22 and 22′ denote N-terminal domains
  • 23 and 23′ denote the finger 1 regions
  • 24 and 24′ denote heel regions
  • 25 and 25′ denote the finger 2 regions
  • 26 and 26′ denote disulfide bonds which connect the 1st and 5th conserved cysteines of each subunit to form the knot-like structure.
  • the heel region from one subunit e.g., 24, and the finger 1 and finger 2 regions, e.g., 23′ and 25′, respectively from the other subunit, interact with one another.
  • These three elements co-operate with one other to define a structure interactive with, and complimentary to the ligand binding interactive surface of the cognate receptor.
  • amino acid sequences defining the finger and heel regions may be utilized from the respective finger and heel region sequences of any known member of the TGF- ⁇ superfamily, identified herein, or from amino acid sequences of a new superfamily member discovered hereafter.
  • FIG. 5 summarizes the amino acid sequences of currently identified TGF- ⁇ superfamily members aligned into finger 1 ( FIG. 5A ), heel ( FIG. 5B ) and finger 2 ( FIG. 5C ) regions.
  • the sequences were aligned by a computer algorithm which in order to optimally align the sequences inserted gaps into regions of amino acid sequence known to define loop structures rather than regions of amino acid sequence known to have conserved amino acid sequence or secondary structure. For example, if possible, no gaps were introduced into amino acid sequences of finger 1 and finger 2 regions defined by ⁇ sheet or heel regions defined by a helix.
  • the dashes (-) indicate a peptide bond between adjacent amino acids.
  • a consensus sequence pattern for each subgroup is shown at the bottom of each subgroup.
  • the aligned sequences were used to produce amino acid sequence alignment patterns which identify amino acid residues that may be substituted by another amino acid or group of amino acids without altering the overall tertiary structure of the resulting construct.
  • the amino acids or groups of amino acids that may be useful at a particular position in the finger and heel regions were identified by a computer algorithm implementing the amino acid hierarchy pattern structure shown in FIG. 3 .
  • the algorithm performs four levels of analysis.
  • level I the algorithm determines whether a particular amino acid residue occurs with a frequency greater than 75% at a specific position within the amino acid sequence. For example, if a glycine residue occurs 8 out of 10 times at a particular position in an amino acid sequence, then a glycine is designated at that position. If the position to be tested consists of all gaps then a gap character ( ⁇ ) is assigned to the position, otherwise, if at least one gap exists then a “z” (standing for any residue or a gap) is assigned to the position. If, no amino acid occurs in 75% of the candidate sequences at a particular position the algorithm implements the Level II analysis.
  • Level II defines pattern sets a, b, d, l, k, o, n, i, and h, wherein l, k, and o share a common amino acid residue.
  • the algorithm determines whether 75% or more of the amino acid residues at a particular position in the amino acid sequence satisfy one of the aforementioned patterns. If so, then the pattern is assigned to that position. It is possible, however, that both patterns l and k may be simultaneously satisfied because they share the same amino acid, specifically aspartic acid. If simultaneous assignment of l and k occurs then pattern m (Level III) is assigned to that position. Likewise, it is possible that both patterns k and o may be simultaneously assigned because they share the same amino acid, specifically glutamic acid.
  • Level III defines pattern sets c, e, m, q, p, and j, wherein m, q, and p share a common amino residue. Pattern q, however, is not tested in the Level III analysis. It is possible that both patterns m and p may be simultaneously satisfied because they share the same amino acid, specifically, glutamic acid. If simultaneous assignment of m and p occurs then pattern r (Level IV) is assigned to that position. If 75% of the amino acids at a pre-selected position in the aligned amino acid sequences satisfy a Level III pattern, then the Level III pattern is assigned to that position. If a Level III pattern cannot be assigned to that position then the algorithm implements a Level IV analysis.
  • Level IV comprises two non-overlapping patterns f and r. If 75% of the amino acids at a particular position in the amino acid sequence satisfy a Level IV pattern then the pattern is assigned to the position. If no Level IV pattern is assigned the algorithm assigns an X representing any amino acid (Level V) to that position.
  • Level I lists in upper case letters in single amino acid code the 20 naturally occurring amino acids.
  • Levels II-V define, in lower case letters, groups of amino acids based upon the amino acid hierarchy set forth in Smith et al., supra. The amino acid sequences set forth in FIGS. 5 and 6 were aligned using the aforementioned computer algorithms.
  • the artisan may use the amino acid sequences shown in FIG. 5 to provide the finger 1, finger 2 and heel regions useful in the production of the morphon constructs of the invention.
  • the amino acid sequence of the new member may be aligned, either manually or by means of a computer algorithm, with the sequences set forth in FIG. 5 to define heel and finger regions useful in the practice of the invention.
  • TGF- ⁇ Superfamily Member SEQ. ID. No. Publication TGF- ⁇ 1 40 Derynck et al. (1987) Nucl. Acids. Res. 15: 3187 TGF- ⁇ 2 41 Burt et al. (1991) DNA Cell Biol. 10: 723-734 TGF- ⁇ 3 42 Ten Dijke et al. (1988) Proc. Natl. Acad. Sci. USA 85: 4715-4719; Derynck et al. (1988) EMBO J. 7: 3737-3743.
  • the invention further contemplates the use of corresponding finger 1 subdomain sequences from the well-known proteins: GDF-5, GDF-7 (as disclosed in U.S. Pat. No. 5,801,014, the entire disclosure of which is incorporated herein by reference); GDF-6 (as disclosed in U.S. Pat. No. 5,770,444, the entire disclosure of which is incorporated herein by reference); and BMP-12 and BMP-13 (as disclosed in U.S. Pat. No. 5,658,882, the entire disclosure of which is incorporated herein by reference).
  • amino acid sequences defining finger 1 regions useful in the practice of the instant invention correspond to the amino acid sequence defining a finger 1 region for any TGF- ⁇ superfamily member identified herein.
  • the finger 1 subdomain can confer at least biological and/or functional attribute(s) which are characteristic of the native protein.
  • Useful intact finger 1 regions include, but are not limited to TGF- ⁇ 1 SEQ. ID. No. 40, residues 2 through 29, TGF- ⁇ 2 SEQ. ID. No. 41, residues 2 through 29, TGF- ⁇ 3 SEQ. ID. No. 42, residues 2 through 29, TGF- ⁇ 4 SEQ. ID. No. 43, residues 2 through 29, TGF- ⁇ 5 SEQ. ID. No. 44, residues 2 through 29, dpp SEQ.
  • the invention further contemplates the use of corresponding heel subdomain sequences from the well-known proteins BMP-12 and BMP-13 (as disclosed in U.S. Pat. No. 5,658,882, the entire disclosure of which is incorporated herein by reference).
  • amino acid sequences defining heel regions useful in the practice of the instant invention correspond to the amino acid sequence defining an intact heel region for any TGF- ⁇ superfamily member identified herein.
  • the heel region can at least influence attributes of the native protein, including functional and/or folding attributes.
  • Useful intact heel regions may include, but are not limited to TGF- ⁇ 1 SEQ. ID. No. 40, residues 35 through 62, TGF- ⁇ 2 SEQ. ID. No. 41, residues 35 through 62, TGF- ⁇ 3 SEQ. ID. No. 42, residues 35 through 62, TGF- ⁇ 4 SEQ. ID. No. 43, residues 35 through 62, TGF- ⁇ 5 SEQ. ID. No.
  • the invention further contemplates the use of corresponding finger 2 subdomain sequences from the well-known proteins BMP-12 and BMP-13 (as disclosed in U.S. Pat. No. 5,658,882, the entire disclosure of which is incorporated herein by reference).
  • amino acid sequences defining finger 2 regions useful in the practice of the instant invention correspond to the amino acid sequence defining an intact finger 2 region for any TGF- ⁇ superfamily member identified herein.
  • the finger 2 subdomain can confer at least folding attribute(s) which are characteristic of the native protein.
  • Useful intact finger 2 regions may include, but are not limited to TGF- ⁇ 1 SEQ. ID. No. 40, residues 65 through 94, TGF- ⁇ 2 SEQ. ID. No. 41, residues 65 through 94, TGF- ⁇ 3 SEQ. ID. No. 42, residues 65 through 94, TGF- ⁇ 4 SEQ. ID. No. 43, residues 65 through 94, TGF- ⁇ 5 SEQ. ID. No.
  • amino acid sequences of the respective finger and heel regions can be altered by amino acid substitution, for example by exploiting substitute residues as disclosed herein or selected in accordance with the principles disclosed in Smith et al. (1990), supra. Briefly, Smith et al. disclose an amino acid class hierarchy similar to the one summarized in FIG. 3 , which can be used to rationally substitute one amino acid for another while minimizing gross conformational distortions of the type which could compromise protein function.
  • many synthetic first finger, second finger, and heel region sequences having only 70% homology with natural regions, preferably 80%, and most preferably at least 90%, can be used to produce the constructs of the present invention.
  • Amino acid sequence patterns showing amino acids preferred at each location in the finger and heel regions also are show in FIGS. 5 and 6 , and are referred to as the: TGF- ⁇ ; Vg/dpp; GDF; and Inhibin subgroup patterns.
  • the amino acid sequences defining the finger 1, heel and finger 2 sequence patterns of each subgroup are set forth in FIGS. 5A, 5B , and 5 C, respectively.
  • the amino acid sequences defining the entire TGF- ⁇ , Vg/dpp, GDF and Inhibin subgroup patterns are set forth in the Sequence Listing as SEQ. ID. Nos. 64, 65, 66, and 67, respectively.
  • the preferred amino acid sequence patterns for each subgroup, disclosed in FIGS. 5A, 5B , and 5 C, and summarized in FIG. 6 enable one skilled in the art to identify alternative amino acids that may be incorporated at specific positions in the finger 1, heel, and finger 2 elements.
  • the amino acids identified in upper case letters in a single letter amino acid code identify conserved amino acids that together are believed to define structural and functional elements of the finger and heel regions.
  • the upper case letter “X” in FIGS. 5 and 6 indicates that any naturally occurring amino acid is acceptable at that position.
  • the lower case letter “z” in FIGS. 5 and 6 indicates that either a gap or any of the naturally occurring amino acids is acceptable at that position.
  • the lower case letters stand for the amino acids indicated in accordance with the pattern definition table set forth in FIG. 5 and identify groups of amino acids which are useful in that location.
  • amino acid sequence subgroup patterns set forth in FIGS. 5 and 6 it is contemplated, for example, that the skilled artisan may be able to predict that where applicable, one amino acid may be substituted by another without inducing disruptive stereochemical changes within the resulting protein construct.
  • the sequence pattern at position 12 contains an “n” which in accordance with FIG. 10 defines an amino acid residue selected from the group consisting of lysine or glutamine. It is contemplated, therefore, that many synthetic finger 1, finger 2 and heel region amino acid sequences, having 70% homology, preferably 80%, and most preferably at least 90% with the natural regions, may be used to produce conformationally active proteins of the invention.
  • the TGF- ⁇ subgroup pattern accommodates the homologies shared among members of the TGF- ⁇ subgroup identified to date including TGF- ⁇ 1, TGF- ⁇ 2, TGF- ⁇ 3, TGF- ⁇ 4, and TGF- ⁇ 5.
  • the generic sequence shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in FIG. 3 .
  • Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa12 is Arg or Lys; Xaa26 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa31 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa33 is Ala, Gly, Pro, Ser, or Thr; Xaa37 is Ile, Leu, Met or Val; Xaa40 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp,
  • the Vg/dpp subgroup pattern accommodates the homologies shared among members of the Vg/dpp subgroup identified to date including dpp, vg-1, vgr-1, 60A, BMP-2A (BMP-2), Dorsalin, BMP-2B (BMP-4), BMP-3, BMP-5, BMP-6, OP-1 (BMP-7), OP-2 and OP-3.
  • the generic sequence below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in FIG. 3 .
  • Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Arg or Lys; Xaa3 is Arg or Lys; Xaa4 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa5 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa9 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa11 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa13 is Ile, Leu, Met or Val; Xaa16 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa23 is Arg, Gln, Glu, or Lys; Xaa26 is Al
  • the GDF subgroup pattern SEQ. ID. No. 66, accommodates the homologies shared among members of the GDF subgroup identified to date including GDF-1, GDF-3, and GDF-9.
  • the generic sequence shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in FIG. 3 .
  • Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa3 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa4 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa5 is Arg, Asn, Asp, Gln, Glu, His, Lys, Ser or Thr; Xaa6 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa7 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met
  • the Inhibin subgroup pattern SEQ. ID. No. 67, accommodates the homologies shared among members of the Inhibin subgroup identified to date including Inhibin ⁇ , Inhibin ⁇ A and Inhibin ⁇ B.
  • the generic sequence shown below, includes both the conserved amino acids (standard three letter code) as well as alternative amino acids (Xaa) present at the variable positions within the sequence and defined by the rules set forth in FIG. 3 .
  • Each Xaa can be independently selected from a group of one or more specified amino acids defined as follows, wherein: Xaa2 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa3 is Arg or Lys; Xaa4 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa5 is Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; Xaa6 is Cys, Ile, Leu, Met, Phe, Trp, Tyr or Val; Xaa7
  • natural-sourced osteogenic protein is a glycosylated dimer, typically having an apparent molecular weight of about 30-36 kDa as determined by SDS-PAGE.
  • the 30 kDa protein gives rise to two glycosylated peptide subunits having apparent molecular weights of about 16 kDa and 18 kDa.
  • the unglycosylated protein which also has osteogenic activity, has an apparent molecular weight of about 27 kDa.
  • the 27 kDa protein gives rise to two unglycosylated polypeptide chains, having molecular weights of about 14 kDa to 16 kDa.
  • the naturally occurring osteogenic proteins are translated as a precursor, having an N-terminal signal peptide sequence typically less than about 30 residues, followed by a “pro” domain that is cleaved to yield the mature C-terminal domain.
  • the signal peptide is cleaved rapidly upon translation, at a cleavage site that can be predicted in a given sequence using the method of Von Heijne (1986) Nucleic Acids Research 14:4683-4691.
  • Osteogenic proteins useful herein include any known naturally-occurring native proteins including allelic, phylogenetic counterpart and other variants thereof, whether naturally-occurring or biosynthetically produced (e.g., including “muteins” or “mutant proteins”), as well as new, osteogenically active members of the general morphogenic family of proteins.
  • useful osteogenically active proteins have polypeptide chains with amino acid sequences comprising a sequence encoded by a nucleic acid that hybridizes, under low, medium or high stringency hybridization conditions, to DNA or RNA encoding reference osteogenic sequences, e.g., C-terminal sequences defining the conserved seven cysteine domains of OP-1, OP-2, BMP2, 4, 5, 6, 60A, GDF5, GDF6, GDF7 and the like.
  • high stringent hybridization conditions are defined as hybridization according to known techniques in 40% formamide, 5 ⁇ SSPE, 5 ⁇ Denhardt's Solution, and 0.1% SDS at 37° C. overnight, and washing in 0.1 ⁇ SSPE, 0.1% SDS at 50° C.
  • Standard stringency conditions are well characterized in commercially available, standard molecular cloning texts. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning , Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984): Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); and B. Perbal, A Practical Guide To Molecular Cloning (1984).
  • FIG. 5C lists the C-terminal residues defining the finger 2 subdomain of various known members of the TGF- ⁇ superfamily. Any one of the proteins on the list that is a poor refolder can be improved by the methods of the invention, as can other known or discoverable family members.
  • constructs of the invention can be manufactured by using conventional recombinant DNA methodologies well known and thoroughly documented in the art, as well as by using well-known biosynthetic and chemosynthetic methodologies using routine peptide or nucleotide chemistries and automated peptide or nucleotide synthesizers.
  • routine methodologies are described for example in the following publications, the teachings of which are incorporated by reference herein: Hilvert, 1 Chem. Biol. 201-3 (1994); Muir et al., 95 Proc. Natl. Acad. Sci. USA 6705-10 (1998); Wallace, 6 Curr. Opin. Biotechnol. 403-10 (1995); Miranda et al., 96 Proc. Natl.
  • Suitable for use in the present invention are naturally-occurring amino acids and nucleotides; non-naturally occurring amino acids and nucleotides; modified or unusual amino acids; modified bases; amino acid sequences that contain post-translaterially modified amino acids and/or modified linkages, cross-links and end caps, non-peptidyl bonds, etc.; and, further including without limitation, those moieties disclosed in the World Intellectual Property Organization ( WIPO ) Handbook on Industrial Property Information and Documentation, Standard St. 25 (1998) including Tables 1 through 6 in Appendix 2, herein incorporated by reference. Equivalents of the foregoing will be appreciated by the skilled artisan relying only on routine experimentation together with the knowledge of the art.
  • the contemplated DNA constructs may be manufactured by the assembly of synthetic nucleotide sequences and/or joining DNA restriction fragments to produce a synthetic DNA molecule.
  • the DNA molecules then are ligated into an expression vehicle, for example an expression plasmid, and transfected into an appropriate host cell, for example E. coli .
  • the contemplated protein construct encoded by the DNA molecule then is expressed, purified, refolded, tested in vitro for certain attributes, e.g., binding activity with a receptor having binding affinity for the template TGF- ⁇ superfamily member, and subsequently tested to assess whether the biosynthetic construct mimics other preferred attributes of the template superfamily member.
  • a library of synthetic DNA constructs can be prepared simultaneously for example, by the assembly of synthetic nucleotide sequences that differ in nucleotide composition in a preselected region.
  • the artisan can choose appropriate finger and heel regions for such a superfamily member (for example from FIGS. 5-6 ). Once the appropriate finger and heel regions have been selected, the artisan then can produce synthetic DNA encoding these regions.
  • a plurality of DNA molecules encoding different linker sequences are included into a ligation reaction containing DNA molecules encoding finger and heel sequences, by judicious choice of appropriate restriction sites and reaction conditions, the artisan may produce a library of DNA constructs wherein each of the DNA constructs encode finger and heel regions but connected by different linker sequences.
  • the resulting DNAs then are ligated into a suitable expression vehicle, i.e., a plasmid useful in the preparation of a phage display library, transfected into a host cell, and the polypeptides encoded by the synthetic DNAs expressed to generate a pool of candidate proteins.
  • the pool of candidate proteins subsequently can be screened to identify specific proteins having binding affinity and/or selectivity for a pre-selected receptor.
  • Screening can be performed by passing a solution comprising the candidate proteins through a chromatography column containing surface immobilized receptor. Then proteins with the desired binding specificity are eluted, for example by means of a salt gradient and/or a concentration gradient of the template TGF- ⁇ superfamily member. Nucleotide sequences encoding such proteins subsequently can be isolated and characterized. Once the appropriate nucleotide sequences have been identified, the lead proteins subsequently can be produced, either by conventional recombinant DNA or peptide synthesis methodologies, in quantities sufficient to test whether the particular construct mimics the activity of the template TGF- ⁇ superfamily member.
  • the tertiary structure of the preferred proteins can subsequently be modulated in order to optimize binding and/or biological activity by, for example, by a combination of nucleotide mutagenesis methodologies aided by the principles described herein and phage display methodologies. Accordingly, an artisan can produce and test simultaneously large numbers of such proteins.
  • DNAs encoding the biosynthetic constructs disclosed herein is performed using known techniques involving the use of various restriction enzymes which make sequence specific cuts in DNA to produce blunt ends or cohesive ends, DNA ligases, techniques enabling enzymatic addition of sticky ends to blunt-ended DNA, construction of synthetic DNAs by assembly of short or medium length oligonucleotides, cDNA synthesis techniques, polymerase chain reaction (PCR) techniques for amplifying appropriate nucleic acid sequences from libraries, and synthetic probes for isolating genes of members of the TGF-b superfamily and their cognate receptors.
  • PCR polymerase chain reaction
  • Various promoter sequences from bacteria, mammals, or insects to name a few, and other regulatory DNA sequences used in achieving expression, and various types of host cells are also known and available.
  • Conventional transfection techniques, and equally conventional techniques for cloning and subcloning DNA are useful in the practice of this invention and known to those skilled in the art.
  • Various types of vectors may be used such as plasmids and viruses including animal viruses and bacteriophages.
  • the vectors may exploit various marker genes which impart to a successfully transfected cell a detectable phenotypic property that can be used to identify which of a family of clones has successfully incorporated the recombinant DNA of the vector.
  • One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer followed by ligation with appropriate ligases.
  • overlapping, complementary DNA fragments may be synthesized using phosphoramidite chemistry, with end segments left unphosphorylated to prevent polymerization during ligation.
  • One end of the synthetic DNA is left with a “sticky end” corresponding to the site of action of a particular restriction endonuclease, and the other end is left with an end corresponding to the site of action of another restriction endonuclease.
  • the complimentary DNA fragments are ligated together to produce a synthetic DNA construct.
  • nucleic acid strands encoding finger 1, finger 2 and heel regions may be isolated from libraries of nucleic acids, for example, by colony hybridization procedures such as those described in Sambrook et al. eds. (1989) “ Molecular Cloning ”, Coldspring Harbor Laboratories Press, NY, and/or by PCR amplification methodologies, such as those disclosed in Innis et al. (1990) “ PCR Protocols, A guide to methods and applications ”, Academic Press.
  • the nucleic acids encoding the finger and heel regions then are joined together to produce a synthetic DNA encoding the biosynthetic single-chain morphon construct of interest.
  • a library of DNA constructs encoding a plurality of morphons may be produced simultaneously by standard recombinant DNA methodologies, such as the ones, described above,
  • cassette mutagenesis or oligonucleotide directed mutagenesis may produce, for example, a series of DNA constructs each of which contain different DNA sequences within a predefined location, e.g., within a DNA cassette encoding a linker sequence.
  • the resulting library of DNA constructs subsequently may be expressed, for example, in a phage display library and any protein constructs that binds to a specific receptor may be isolated by affinity purification, e.g., using a chromatographic column comprising surface immobilized receptor (see section V below). Once molecules that bind the preselected receptor have been isolated, their binding and agonist properties may be modulated using the empirical refinement techniques also discussed in section V, below.
  • nucleotide codons competent to encode amino acids including arginine (Arg), glutamic acid (Glu) and aspartic acid (Asp) also are well known and described in the art. See, for example, Lehninger, Biochemistry , (Worth Publishers, N.Y., N.Y.) Standard codons encoding arginine, glutamic acid and aspartic acid are: Arg: CGU, CGC, CGA, CGG, AGA, AGG; Glu: GAA, GAG; and Asp: GAU, GAC.
  • Chimeric constructs of the invention can readily be constructed by aligning the nucleic acid sequences of protein regions, or domains to be switched, and identifying compatible splice sites and/or constructing suitable crossover sequences using PCR overlap extension.
  • the mutant forms of TGF- ⁇ family members of the present invention can be produced in bacteria using standard, well-known methods. Full-length mature forms or shorter sequences defining only the C-terminal seven cysteine domain can be provided to the host cell. It may be preferred to modify the N-terminal sequences of the mutant forms of the protein in order to optimize bacterial expression.
  • the preferred form of native OP-1 for bacterial expression is the sequence encoding the mature, active sequence (residues 293-431 of SEQ No. 39 or a fragment thereof encoding the C-terminal seven cysteine domain (e.g., residues 330-431 of SEQ ID NO: 39).
  • a methionine can be introduced at position 293, replacing the native serine residue, or it can precede this serine residue.
  • a methionine can be introduced anywhere within the first thirty-six residues of the natural sequence (residues 293-329), up to the first cysteine of the TGF- ⁇ domain.
  • the DNA sequence further can be modified at its N-terminus to improve purification, for example, by adding a “hexa-his” tail to assist purification on an IMAC column; or by using a FB leader sequence, which facilitates purification on an IgG/column.
  • the synthetic nucleic acids preferably are inserted into a vector suitable for overexpression in the host cell of choice.
  • Any expression vector can be used, so long as it is capable of directing the expression of a heterologous protein such as a BMP in the host cell of choice.
  • Useful vectors include plasmids, phagemids, mini chromosomes and YACs, to name a few. Other vector systems are well known and characterized in the art.
  • the vector typically includes a replicon, one or more selectable marker gene sequences, and means for maintaining a high copy number of the vector in the host cell.
  • Well known selectable marker genes include antibiotics like ampicillin, tetracycline and the like, as well as resistance to heavy metals.
  • Useful selectable marker genes for use in yeast cells include the URA3, LEU2, HIS3 or TRP1 gene for use with an auxotrophic yeast mutant host.
  • the vector also includes a suitable promoter sequence for expressing the gene of interest and which may or may not be inducible, as desired, as well as useful transcription and translation initiation sites, terminators, and other sequences that can maximize transcription and translation of the gene of interest.
  • Well characterized promotors particularly useful in bacterial cells include the lac, tac, trp, and tpp promoters, to name a few. Promoters useful in yeast include ADHI, ADHII, or PHO5 promoter, for example.
  • Suitable host cells include microbial cells such as Bacillus subtilis ( B. subtilis ), species of Pseudomonas, Escherichia coli ( E. coli ), and yeast cells, e.g., Saccharomyces cereviceae .
  • Other hosts cells for example mammalian cells such as CHO, can be used.
  • the gene of interest can be transformed into the host cell of choice using standard microbiology techniques (electroporation or calcium chloride, for example) and the cells induced to grow under suitable conditions.
  • Cell culturing media are well described in the art, including numerous well known texts, including Sambrook, et al.
  • Useful media include LB (Luria's Broth) and Dulbecco's DMEM.
  • the overexpressed protein can be collected from insoluble, refractile inclusion bodies by standard techniques, including cell lysis or mechanical disruption of the cell (Frenchpress, SLM Instruments, Inc, for example) followed by centrifugation and resolubilization (see below).
  • the gene is to be expressed in E. coli , it is cloned into an appropriate expression vector. This can be accomplished by positioning the engineered gene downstream of a promoter sequence such as Trp or Tac, and/or a gene coding for a leader peptide such as fragment B of protein A (FB). During expression, the resulting fusion proteins accumulate in refractile bodies in the cytoplasm of the cells, and may be harvested after disruption of the cells by French press or sonication. The isolated refractile bodies then are solubilized, and the expressed proteins folded and the leader sequence cleaved, if necessary, by methods already established with many other recombinant proteins.
  • a promoter sequence such as Trp or Tac
  • FB fragment B of protein A
  • DNA vector design for transfection into mammalian cells should include appropriate sequences to promote expression of the gene of interest as described herein, including appropriate transcription initiation, termination, and enhancer sequences, as well as sequences that enhance translation efficiency, such as the Kozak consensus sequence.
  • Preferred DNA vectors also include a marker gene and means for amplifying the copy number of the gene of interest.
  • the best characterized transcription promoters useful for expressing a foreign gene in a particular mammalian cell are the SV40 early promoter, the adenovirus promoter (AdMLP), the mouse metallothionein-I promoter (mMT-I), the Rous sarcoma virus (RSV) long terminal repeat (LTR), the mouse mammary tumor virus long terminal repeat (MMTV-LTR), and the human cytomegalovirus major intermediate-early promoter (hCMV).
  • AdMLP adenovirus promoter
  • mMT-I mouse metallothionein-I promoter
  • RSV Rous sarcoma virus
  • LTR Rous sarcoma virus
  • MMTV-LTR mouse mammary tumor virus long terminal repeat
  • hCMV human cytomegalovirus major intermediate-early promoter
  • DHFR as a selectable, amplifiable marker gene in transfected chinese hamster ovary cell lines (CHO cells) is particularly well characterized in the art.
  • Other useful amplifiable marker genes include the adenosine deaminase (ADA) and glutamine synthetase (GS) genes.
  • COS cells provide high levels of transient gene expression, providing a useful means for rapidly screening the biosynthetic constructs of the invention.
  • COS cells typically are transfected with a simian virus 40 (SV40) vector carrying the gene of interest. The transfected COS cells eventually die, thus preventing the long term production of the desired protein product.
  • SV40 simian virus 40
  • transient expression does not require the time consuming process required for the development of a stable cell line, and thus provides a useful technique for testing preliminary constructs for binding activity.
  • the various cells, cell lines and DNA sequences that can be used for mammalian cell expression of the single-chain constructs of the invention are well characterized in the art and are readily available.
  • Other promoters, selectable markers, gene amplification methods and cells also may be used to express the proteins of this invention.
  • Particular details of the transfection, expression, and purification of recombinant proteins are well documented in the art and are understood by those having ordinary skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in mammalian cell expression systems can be found in a number of texts and laboratory manuals in the art, such as, for example, F. M. Ausubel et al, ed., Current Protocols in Molecular Biology , John Wiley & Sons, New York, (1989).
  • the protein once isolated from inclusion bodies, is solubilized using a denaturant or chaotropic agent such as guanidine HCl or urea, preferably in the range of about 4-9 M and at an elevated temperature (e.g., 25-37° C.) and/or basic pH (8-10).
  • a denaturant or chaotropic agent such as guanidine HCl or urea
  • the proteins can be solubilized by acidification, e.g., with acetic acid or trifluoroacetic acid, generally at a pH in the range of 1-4.
  • a reducing agent such as ⁇ -mercaptoethanol or dithiothreitol (DTT) is used in conjunction with the solubilizing agent.
  • the solubilized heterologous protein can be purified further from solubilizing chaotropes by dialysis and/or by known chromatographic methods such as size exclusion chromatography, ion exchange chromatography, or reverse phase high performance liquid chromatography (RP-HPLC), for example.
  • chromatographic methods such as size exclusion chromatography, ion exchange chromatography, or reverse phase high performance liquid chromatography (RP-HPLC), for example.
  • the solubilized protein can be refolded as follows.
  • the dissolved protein is diluted in a refolding medium, typically a Tris-buffered medium having a pH in the range of about pH 5.0-10.0, preferably in the range of about pH 6-9 and one which includes a detergent and/or chaotropic agent.
  • a refolding medium typically a Tris-buffered medium having a pH in the range of about pH 5.0-10.0, preferably in the range of about pH 6-9 and one which includes a detergent and/or chaotropic agent.
  • a refolding medium typically a Tris-buffered medium having a pH in the range of about pH 5.0-10.0, preferably in the range of about pH 6-9 and one which includes a detergent and/or chaotropic agent.
  • Useful commercially available detergents can be ionic, nonionic or zwitterionic, such as NP40 (Nonidet 40), CHAPS (such as 3-[(3-chola
  • Useful chaotropic agents include guanidine, urea, or arginine.
  • the detergent or chaotropic agent is present at a concentration in the range of about 0.1-10M, preferably in the range of about 0.5-4M.
  • CHAPS is the detergent, it preferably comprises about 0.5-5% of the solution, more preferably about 1-3% of the solution.
  • the solution also includes a suitable redox system such as the oxidized and reduced forms of glutathione, DTT, ⁇ -mercaptoethanol, ⁇ -mercaptomethanol, cysteine or cystamine, to name a few.
  • the redox systems are present at ratios of reductant to oxidant in the range of about 1:1 to about 5:1.
  • the ratio of reduced glutathione to oxidized glutathione is preferably is in the range of about 0.5 to 5; more preferably 1 to 1; and most preferably 2 to 1 of reduced form to oxidized form.
  • the buffer also contains a salt, typically NaCl, present in the range of about 0.25M-2.5 M, preferably in the range of about 0.5-1.5M, most preferably in the range of about 1M.
  • a salt typically NaCl
  • the protein concentration for a given refolding reaction is in the range of about 0.001-1.0 mg/ml, more preferably it is in the range of about 0.05-0.25 mg/ml, most preferably in the range of about 0.075-0.125 mg/ml.
  • higher concentrations tend to produce more aggregates.
  • heterodimers for example an OP1/BMP2 or BMP2/BMP6 heterodimer
  • the individual proteins are provided to the refolding buffer in equal amounts.
  • the refolding reaction takes place at a temperature range from about 4° C. to about 25° C. More preferably, the refolding reaction is performed at 4° C., and allowed to go to completion. Refolding typically is complete in about one to seven days, generally within 16-72 hours or 24-48 hours, depending on the protein. As will be appreciated by the skilled artisan, rates of refolding can vary by protein, and longer and shorter refolding times are contemplated and within the scope of the present invention.
  • a “good refolder” protein is one where at least 20% of the protein is present in dimeric form following a folding reaction when compared to the total protein in the refolding reaction, as measured by any of the refolding assays described herein and without requiring further purification.
  • Native BMPs that are considered in the art to be “good refolder” proteins include BMP2, CDMP1, CDMP2 and CDMP3. BMP-3 also refolds reasonably well. In contrast, a “poor refolder” protein yields less than 1% of properly-folded protein.
  • Properly refolded dimeric proteins readily can be assessed using any of a number of well known and well characterized assays.
  • any one or more of three assays, all well known and well described in the art, and further described below can be used to advantage.
  • Useful refolding assays include one or more of the following.
  • the presence of dimers can be detected visually either by standard SDS-PAGE in the absence of a reducing agent such as DTT or by HPLC (e.g., C18 reverse phase HPLC).
  • BMP dimeric proteins have an apparent molecular weight in the range about 28-36 kDa, as compared to monomeric subunits, which have an apparent molecular weight of about 14-18 kDa.
  • the dimeric protein can readily be visualized on an electrophoresis gel by comparison to commercially available molecular weight standards.
  • the dimeric protein also elutes from a C18 RP HPLC (45-50% acetonitrile: 0.1% TFA) at about 19 minutes (mammalian produced hOP-1 elutes at 18.95 minutes).
  • a second assay evaluates the presence of dimer by its ability to bind to hydroxyapatite. Properly-folded dimer binds a hydroxyapatite column well in the presence of 0.1-0.2M NaCl (dimer elutes at 0.25 M NaCl) as compared to monomer, which does not bind substantially at those concentrations (monomer elutes at 0.1M NaCl).
  • a third assay evaluates the presence of dimer by the protein's resistant to trypsin or pepsin digestion.
  • the folded dimeric species is substantially resistant to both enzymes, particularly trypsin, which cleaves only a small portion of the N-terminus of the mature protein, leaving a biologically active dimeric species only slightly smaller in size than the untreated dimer.
  • the monomer is substantially degraded.
  • the protein is subjected to an enzyme digest using standard conditions, e.g., digestion in a standard buffer such as 50 mM Tris buffer, pH 8, containing 4 M urea, 100 mM NaCl, 0.3% Tween-80 and 20 mM methylamine. Digestion is allowed to occur at 37° C. for on the order of 16 hours, and the product visualized by any suitable means, preferably SDS-PAGE.
  • the biological activity of the refolded TGF- ⁇ family protein readily can be assessed by any of a number of means.
  • a BMP's ability to induce endochondral bone formation can be evaluated using the well characterized rat subcutaneous bone assay, described in the art and in detail below.
  • bone formation is measured by histology, as well as by alkaline phosphatase and/or osteoclacin production.
  • osteogenic proteins having high specific bone forming activity such as OP-1, BMP-2, BMP-4, BMP5 and BMP6, also induce alkaline phosphatase activity in an in vitro rat osteoblast or osteosarcoma cell-based assay.
  • Such assays are well described in the art and are detailed herein below.
  • osteogenic proteins having low specific bone forming activity such as CDMP-1 and CDMP-2, for example, do not induce similar levels of alkaline phosphatase activity in the cell based osteoblast assay.
  • the assay thus provides a ready method for evaluating biological activity mutants of BMPs.
  • CDMP 1, CDMP2 and CMDP3 all are competent to induce bone formation, although with a lower specific activity than BMP2, BMP4, BMP5, BMP6 or OP-1.
  • BMP2, BMP4, BMP5, BMP6 and OP-1 all can induce articular cartilage formation, albeit with a lower specific activity than CDMP 1, CDMP2 or CDMP3.
  • a CDMP mutant competent to induce alkaline phosphatase activity in the cell-based assay of Example 5 is expected to demonstrate a higher specific bone forming activity in the rat animal bioassay.
  • an OP-1 mutant containing a substitution present in a corresponding position of a CDMP 1, CDMP2 or CDMP3 protein, and competent to induce bone in the rat assay but not to induce alkaline phosphatase activity in the cell based assay, is expected to have a higher specific articular cartilage inducing activity in an in vivo articular cartilage assay.
  • a suitable in vitro assay for CDMP activity utilizes mouse embyronic osteoprogenitor or carcinoma cells, such as ATDC5 cells. See Example 6, below.
  • TGF- ⁇ activity can be readily evaluated by the protein's ability to inhibit epithelial cell growth.
  • a useful, well characterized in vitro assay utilizes mink lung cells or melanoma cells. See Example 7.
  • Other assays for other members of the TGF-8 superfamily are well described in the literature and can be performed without undue experimentation.
  • the resulting chimeric proteins can be provided to an individual as part of a therapy to enhance, inhibit, or otherwise modulate in vivo events, such as but not limited to, the binding interaction between a TGF- ⁇ superfamily member and one or more of its cognate receptors.
  • the constructs may be formulated in a pharmaceutical composition, as described below, and may be administered in morphogenic effective amounts by any suitable means, preferably directly or systematically, e.g., parenterally or orally.
  • Resulting DNA constructs encoding preferred chimeric proteins can also be administered directly to a recipient for gene therapeutic purposes; such DNAs can be administered with or without carrier components, or with or without matrix components. Alternatively, cells transferred with such DNA constructs can be implanted in a recipient. Such materials and methods are well-known in the art.
  • the therapeutic composition preferably comprises part of an aqueous solution.
  • the solution preferably is physiologically acceptable so that in addition to delivery of the desired construct to the patient, the solution does not otherwise adversely affect the patient's electrolyte and volume balance.
  • the aqueous medium for the therapeutic molecule thus may comprise, for example, normal physiological saline (0.9% NaCl, 0.15M), pH 7-7.4 or other pharmaceutically acceptable salts thereof.
  • Formulations may include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like.
  • Formulations for direct administration in particular, may include glycerol and other compositions of high viscosity.
  • Biocompatible, preferably bioresorbable polymers including, for example, hyaluronic acid, collagen, tricalcium phosphate, polybutyrate, polylactide, polyglycolide and lactide/glycolide copolymers, may be useful excipients to control the release of the morphogen in vivo.
  • Formulations for inhalation administration may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • therapeutic molecules may be administered alone or in combination with other molecules known to effect tissue morphogenesis, i.e., molecules capable of tissue repair and regeneration and/or inhibiting inflammation.
  • useful cofactors for stimulating bone tissue growth in osteoporotic individuals include but are not limited to, vitamin D 3 , calcitonin, prostaglandins, parathyroid hormone, dexamethasone, estrogen and IGF-I or IGF-II.
  • Useful cofactors for nerve tissue repair and regeneration may include nerve growth factors.
  • Other useful cofactors include symptom-alleviating cofactors, including antiseptics, antibiotics, antiviral and antifungal agents and analgesics and anesthetics.
  • Therapeutic molecules further can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers.
  • such compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops or aerosols.
  • the composition may include the biosynthetic construct dispersed in a fibrinogen-thrombin composition or other bioadhesive such as is disclosed, for example in PCT US91/09275, the disclosure of which is incorporated herein by reference.
  • the composition then may be painted, sprayed or otherwise applied to the desired tissue surface.
  • the compositions can be formulated for parenteral or oral administration to humans or other mammals in therapeutically effective amounts, e.g., amounts which provide appropriate concentrations of the morphon to target tissue for a time sufficient to induce the desired effect.
  • any commercially available preservation solution may be used to advantage.
  • useful solutions known in the art include Collins solution, Wisconsin solution, Belzer solution, Eurocollins solution and lactated Ringer's solution.
  • a detailed description of preservation solutions and useful components may be found, for example, in U.S. Pat. No. 5,002,965, the disclosure of which is incorporated herein by reference.
  • the protein constructs for example those based upon members of the Vg/dpp subgroup, will also exhibit high levels of activity in vivo when combined with a matrix. See for example, U.S. Pat. No. 5,266,683 the disclosure of which is incorporated by reference herein.
  • the currently preferred matrices are xenogenic, allogenic or autogenic in nature. It is contemplated, however, that synthetic materials comprising polylactic acid, polyglycolic acid, polybutyric acid, derivatives and copolymers thereof can also be used to generate suitable matrices.
  • Preferred synthetic and naturally derived matrix materials their preparation, methods for formulating them with the morphogenic proteins of the invention, and methods of administration are well known in the art and so are not discussed in detailed herein. See for example, U.S. Pat. No. 5,266,683, the disclosure of which is herein incorporated by reference. It is further contemplated that binding to, adherence to or association with a matrix or the metal surface of a prosthetic device is an attribute that can be altered using the materials and methods disclosed herein.
  • devices comprising a matrix and an osteoactive construct of the present invention having enhanced matrix-adherent properties can be used as a slow-release device.
  • the skilled artisan will appreciate the variation and manipulations now possible in light of the teachings herein.
  • the concentration of the compounds described in a therapeutic composition will vary depending upon a number of factors, including the morphogenic effective amount to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration:
  • the preferred dosage of drug to be administered also is likely to depend on such variables as the type and extent of a disease, tissue loss or defect, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound, the presence and types of excipients in the formulation, and the route of administration.
  • the therapeutic molecules of this invention may be provided to and individual where typical doses range from about 10 ng/kg to about 1 g/kg of body weight per day; with a preferred dose range being from about 0.1 mg/kg to 100 mg/kg of body weight.
  • the present invention relates to four types of modified TGF- ⁇ family protein constructs: (1) TGF- ⁇ family proteins which are truncated at the N-terminal region, (2) “latent” proteins that can be activated upon cleavage, including, but not limited to, release of an N-terminal sequence (e.g., by acid cleavage or protease treatment), (3) fusion proteins with specific binding capabilities and (4) heterodimers consisting of naturally-occurring or modified subunits of TGF- ⁇ family members.
  • Particular species of these morphogen constructs are described in detail below. The species exemplified below generally relate to modified morphogen or osteogenic protein constructs, but the skilled practitioner will appreciate that these constructs are representative of similar constructs that can be generated with other members of the TGF- ⁇ super family.
  • the attributes of native BMPs or other members of the TGF- ⁇ superfamily of proteins, including heterodimers and homodimers thereof, are altered by modifying the N-terminus of a native protein to alter one or more biological properties of a BMP or TGF- ⁇ superfamily member.
  • TGF- ⁇ superfamily proteins that (1) are expressed recombinantly in prokaryotic or eukaryotic cells or synthesized using polypeptide synthesizers; (2) have altered folding attributes; (3) have altered solubility under neutral pHs, including but not limited to physiologically compatible conditions; (4) have altered isoelectric points; (5) have altered stability; (6) have an altered tissue or receptor specificity; (7) have a re-designed, altered biological activity; and/or (8) have altered binding or adherence properties to solid surfaces, such as but not limited to, biocompatible matrices or metals.
  • the present invention can provide mechanisms for designing quick-release, slow-release and/or timed-release formulations containing a preferred protein construct.
  • modified proteins having altered surface-binding/surface-adherent properties can be designed and selected.
  • Surfaces of particular significance include, but are not limited to, solid surfaces which can be naturally-occurring such as bone; or porous particulate surfaces such as collagen or other biocompatible matrices; or the flabricated surfaces of prosthetic implants, including metals.
  • virtually any surface can be assayed for differential binding of constructs.
  • the present invention embraces a diversity of functional molecules having alterations in their surface-binding/surface-adherent properties, thereby rendering such constructs useful for altered in vivo applications, including slow-release, fast-release and/or timed-release formulations.
  • stability alterations can be routinely monitored using well-known techniques of circular dichroism other indices of stability as a function of denaturant concentration or temperature.
  • solubility it is possible to manipulate this attribute so that a protein construct is either more or less soluble under physiologically-compatible conditions and it consequently diffuses readily or remains localized, respectively, when administered in vivo.
  • altered stability can also be used to practical advantage for shelf-life, storage and/or shipping considerations. Furthermore, on a related matter, altered stability can also directly affect dosage considerations thereby, for example, reducing the cost of treatment.
  • a particularly significant class of constructs are those having altered binding to solubilized carriers or excipients.
  • an altered BMP having enhanced binding to a solubilized carrier such as hyaluronic acid permits the skilled artisan to administer an injectable formulation at a defect site without loss or dilution of the BMP by either diffusion or body fluids. Thus localization is maximized.
  • a solubilized carrier such as hyaluronic acid
  • another class of constructs having altered binding to body/tissue components can be exploited.
  • an altered BMP having diminished binding to an in-situ inhibitor can be used to enhance repair of certain tissues in vivo.
  • cartilage tissue is associated with certain proteins found in body fluids and/or within cartilage per se that can inhibit the activity of native BMPs.
  • Chimeric constructs with altered binding properties can overcome the effects of these in-situ inhibitors thereby enhancing repair, etc.
  • the skilled artisan will appreciate the variations made possible by the instant teachings.
  • OP-1 there are different forms of OP-1, such as 23k, 17k, and variable amounts of 15k, whereby the typical OP-1 preparation contains all these species.
  • N-terminal sequencing of purified mature OP-1 has revealed heterogeneity showing that the N-terminus can be more or less truncated.
  • ROS activity is greatest among the 15k species.
  • truncated mutant H2469 has relatively high activity by comparison with the CHO-derived OP-1 standard.
  • initial maturation occurs in pro-OP-1 at the RXXR site resulting in the 17k species
  • a secondary maturation by a different protease produces the most active 15k species. Trypsin cleavage can mimic this secondary activation.
  • cleavage activity may differ based on the system used (mammalian or prokaryote).
  • a mammalian system may require that the morphogen construct include a pro region, which in the context of the construct, could disrupt folding and consequently will result (in the mammalian system), in complete intracellular degradation with no protein at the end. It may also be desirable to produce other constructs that include the pro-protein form.
  • the pro-domain can be considered as another N-terminal element which can be cleaved to obtain increased activity.
  • the uncleaved pro-protein can be utilized to take advantage of its attributes (relating to solubility and activity).
  • mutant proteins of the present invention exhibit improved biological activity as well as extended half-life. Further, increased activity observed with the truncated proteins of the present invention may be due to elimination of basic residues and/or the lowering of the protein's isoelectric point. Biological activity and improved refolding can be enhanced when the modified proteins of the present invention are combined with the modifications described in copending application Ser. No. ______ [Atty Docket No. STK-076, filed on ______] and Ser. No. ______ [Atty Docket No. STK-077, filed on ______], the disclosures of which are incorporated herein by reference.
  • Additional modified proteins of the invention comprise peptides of non-morphogen origin fused to the N-terminus of a morphogen 7-cysteine domain. See e.g., FIGS. 7A-7E .
  • the resulting N-terminal fusion proteins have additional biological or biochemical properties not present in the unmodified morphogen from which the fusion is derived. Fusions of this type comprise a morphogen 7-cysteine domain fused at its N-terminus to a protein, or protein fragment, such as a collagen binding domain, an FB domain of protein A, or a hexa-histidine region.
  • H2440 is OP-1 with a hexa-his tag attached to its N-terminus as a binding domain for IMAC (immobilized metal affinity chromatography) resin.
  • IMAC immobilized metal affinity chromatography
  • OP-1 constructs that can target specific sites.
  • an OP-1 with a N-terminal decapeptide collagen binding domain was constructed, H2487, in which the decapeptide was placed 7 residues upstream from the first cysteine (see FIG. 7A ) to obtain specific and tight binding of OP-1 to bone matrix.
  • This new construct was successfully refolded and active in the ROS assay, thereby indicating specific bone forming activity.
  • Other binding domains can be used similarly to direct activity.
  • OP-1 can also be engineered to specifically adhere to prosthetic devices.
  • Other peptides such as a peptide derived from Clostridium collagenase, can also be explored for collagen binding properties.
  • Modifications of the leader sequence of a BMP or other TGF- ⁇ family members can also affect solubility, activity, and expression of the protein.
  • construct H2528 which utilizes CDMP-3 (thought to be useful for tendon repair) engineered with a leader sequence as the FB subdomain of staphylococcus aureus protein A, has improved expression of the osteogenic protein.
  • constructs of the present invention can be engineered to contain a variety of specialized, functional domains that can be attached to the N-terminus of the TGF- ⁇ family protein, provided that steric interference and the consequent reduction in biological activity are taken into account.
  • Such constructs may require at least a minimum spacing of the N-terminal addition from the 7-cysteine domain to avoid inhibition of activity or folding.
  • minimum spacing requirements will depend upon the steric properties of the added moiety and the ultimate intended activity of the modified construct, so that both the specialized domain and the TGF- ⁇ family protein will retain their intended activities.
  • the present invention also takes advantage of the surprising discovery of the extent to which the N-terminus can effect the solubility and activity of the fusion proteins, since truncations of the OP-1 N-terminus had no negative effects on the protein. In addition, the crystal structure of OP-1 had not revealed any topological information regarding the N-terminus.
  • N-terminal fusion proteins described herein are useful for providing latent (i.e. inactive) forms of a protein that can be cleaved to produce an active protein at a desired time and location.
  • a modified morphogen containing a collagen binding domain e.g. H2487, shown in FIG. 7A
  • a desired tissue locus e.g. a locus containing an implanted collagen matrix
  • Cleavage can result from conditions endogenous to the target locus (e.g., naturally-occurring proteases) or can be the result of administration of specific proteases or other factors (e.g., acidification of a locus).
  • a very specific protease cleavage site may be engineered, e.g., for a protease found in a fracture site, allowing selective, delayed, and/or gradual activation of OP-1 at the site of implant.
  • constructs to alter refolding, solubility, activity and expression can be designed by replacing the native leader sequence of one TGF- ⁇ superfamily protein with the native leader sequence of another TGF- ⁇ family member.
  • the construct H2549 has the N-terminus of BMP-2 transposed onto OP-1.
  • N-terminal fusion protein monomers as described above do not form active homodimers without cleavage of the leader sequence, active heterodimers are formed between those proteins and unmodified monomers of TGF- ⁇ family proteins. Accordingly, such heterodimers can be used to provide proteins to a target site by virtue of the N-terminal non-TGF- ⁇ family protein domain attached to the fusion protein, such as a collagen binding domain.
  • design features can be used to enhance purification of heterodimers. Purification can be facilitated by accentuating purification differences between two kinds of subunits, for instance, by adding a hexa-histidine.
  • a mixed refolding would provide a mixture of two homodimers and the heterodimer, which provides three separable species.
  • an N-terminal fusion protein containing a hexa-histidine domain e.g. H2440, shown in FIG. 7B ) which binds an IMAC column, is useful to aid in purification of the fusion protein, which can subsequently be activated by cleavage of the N-terminal domain.
  • E. coli expression for construction of heterodimers of the present invention is preferred, because the practitioner can adjust the ratio of each monomer for optimal yields of heterodimer. In addition, this method is very rapid.
  • E, D, E, and R charged amino acids
  • BMP-2 the yield of heterodimers were excellent. There is an exceptionally high yield of heterodimer, more than the theoretically expected 50% heterodimer and 25% of each homodimer.
  • BMP-2 associates more readily with OP-1 than with itself, or faster than OP-1 reassociates with itself.
  • the BMP-2 may act as chaperone for folding.
  • Another experiment also showed heterodimer formation between BMP-2 and the H2447 mutant, OP-1 (no hexa-his tag), which also associated readily, generating good yields of heterodimer.
  • Heterodimers were also made between FB-OP-1 (H2521) and BMP-2. Heterodimers of truncated OP-1, H2469 (retaining 15 residues upstream of the first cysteine), and BMP-5 (H2475); and H2469 and CDMP-2 (H2471) have also been constructed.
  • heterodimers of hexa-his-OP-1 H2440 and BMP-2 (H2142) have much greater activity in a ROS assay than the homodimers.
  • the hexa-his-OP-1 homodimer had very low activity.
  • the homodimer of BMP-2 had better activity.
  • OP-1/BMP-2 heterodimer was far more active than either parent homodimer. In this assay the heterodimer had only about 3-fold less activity than the CHO derived OP-1 standard.
  • the heterodimer of OP-1 without the hexa-his tag, (H2447) with BMP-2 had similar activity.
  • H2447 is a refolding mutant with modifications in finger-2 and had relatively lower activity as a homodimer.
  • Heterodimers of OP-1 (H2469)/BMP-5 (H2475) and OP-1 (H2469)/CDMP-2 (H2471) provided a good result on a ROS assay (2.5-3+).
  • an OP-1/BMP-2 heterodimer was constructed, expressed in E. coli , and refolded in vitro.
  • H2447/BMP-2 heterodimers and H2440/BMP-2 heterodimers were created by E. coli expression and refolded in vitro under physiological conditions. Based on SDS-PAGE analysis, most of the material readily combined to form a heterodimeric species. Additional species are formed using heterodimers comprising a non-morphogen domain.
  • N-terminal fused to morphogens such as collagen binding domain fused to OP-1 (H2487), hexa-histidine fused to OP-1 (H2440), and FB domain of Protein A fused to OP-1 (H2521), and FB-domain fused to the hexa-histidine/OP-1 construct H2440 (H2525).
  • Active heterodimers can also be constructed from two BMPs or other TGF- ⁇ family proteins that were expressed in different systems. Some constructs are expressed better and are more active when expressed in certain systems over others. One can express each construct in the environment best suited for its expression and then form active heterodimers with them. For example, H2223, a mutant OP-1, is expressed in CHO cells, a mammalian expression system, while H2525 ( FIG. 7D ), FB-domain OP-1, is best expressed in E. coli , a bacterial expression system.
  • the activity of the heterodimers can be manipulated by changing the two proteins used. For example, a heterodimer of H2487, OP-1 with a decapeptide collagen binding site, and CDMP3 can be formed. This heterodimer will have an activity different from a H2487 and BMP-2 heterodimer.
  • chimeric proteins having certain desired attribute(s) making them suitable for specific in vivo applications (see at least Sections I.B., II., and III. Examples 1-4, 8 and 11 for exemplary embodiments of the foregoing chimeric proteins).
  • chimeric proteins having altered solubility attributes can be used in vivo to manipulate morphogenic effective amounts provided to a recipient. That is, increased solubility can result in increased availability; diminished solubility can result in decreased availability.
  • systemically administered chimeric proteins can be immediately available/have immediate morphogenic effects, whereas locally administered chimeric proteins can be available more slowly/have prolonged morphogenic effects.
  • locally administered chimeric proteins can be available more slowly/have prolonged morphogenic effects.
  • chimeric proteins having altered stability attributes can be used in vivo to manipulate morphogenic effective amounts provided to a recipient. That is, increased stability can result in increased half-life because turnover in vivo is less; diminished stability can result in decreased half-life and availability because turnover in vivo is more.
  • systemically administered chimeric proteins can either be immediately available/have immediate morphogenic effects achieving a bolus-type dosage or can be available in vivo for prolonged periods/have prolonged morphogenic effects achieving a sustained release type dosage.
  • increased versus diminished stability attributes are preferred given the facts and circumstances at hand. Optimization of such parameters requires routine experimentation and ordinary skill.
  • altered stability can also be used to practical advantage for improving shelf-life, storage and/or shipping considerations.
  • altered stability can also directly affect dosage considerations thereby, for example, reducing the cost of treatment.
  • chimeric proteins having a combination of altered attributes can be used in vivo to manipulate morphogenic effective amounts provided to a recipient. That is, by designing a chimeric protein with a combination of specific altered attributes, morphogenic effective amounts can be administered in a timed-release fashion; dosages can be regulated both in terms of amount and duration; treatment regimens can be initiated at low doses systemically or locally followed by a transition to high doses, or vice versa; to name but a few paradigms. The skilled artisan will appreciate when low versus high morphogenic effective amounts are suitable under the facts and circumstances at hand. Optimization of such parameters requires routine experimentation and ordinary skill.
  • chimeric proteins having one or more altered attributes are useful to overcome inherent deficiencies in development.
  • Chimeric proteins having one or more altered attributes can be designed to circumvent an inherent defect in a host's native morphogenic signaling system.
  • a chimeric protein of the present invention can be used to bypass a defect in a native receptor in a target tissue, a defect in an intracellular signaling pathway, and/or a defect in other events which are reliant on the attributes of a subdomain(s) associated with recognition of a moiety per se as opposed to the attributes associated with function/biological activity which are embodied in a different subdomain(s).
  • the skilled artisan will appreciate when such chimeric proteins are suitable given the facts and circumstances at hand. Optimization requires routine experimentation and ordinary skill.
  • FIG. 8 shows the nucleotide and corresponding amino acid sequence for the OP-1 C-terminal seven cysteine domain. Knowing these sequences permits identification of useful restriction sites for engineering in mutations by, for example, cassette mutagenesis or the well-known method of Kunkel (mutagenesis by primer extension using m13-derived single-stranded templates) or by the well-known PCR methods, including overlap extension.
  • An exemplary mutant of OP-1 is H2460, with 4 amino acid changes in the finger 2 sub-domain and an amino acid change in the last C-terminal amino acid, constructed as described below. It is understood by the skilled artisan that the mutagenesis protocol described is exemplary only, and that other means for creating the constructs of the invention are well-known and well described in the art.
  • OP-1 mutant H2460 Four amino acid changes were introduced into the OP-1 finger 2 sub-domain sequence by means of standard polymerase chain reactions using overlap extension technique, resulting in OP-1 mutant H2460.
  • the four changes in the finger 2 region were N6>S, R25>E, N26>D and R30>E.
  • This mutant also contained a further change, H35>R, of the C-terminal residue.
  • the template for these reactions was the mature domain of a wild type OP-1 cDNA clone, which had been inserted into an E. coli expression vector engineered with an ATG start codon at the beginning of the mature region.
  • the ATG had been introduced by PCR using as a forward primer a synthetic oligonucleotide of the following sequence: ATG TCC ACG GGG AGC AAA CAG (SEQ ID NO: 36), encoding M S T G S K Q (SEQ ID NO: 37).
  • the PCR reaction was done in combination with an appropriate back-primer complementary to the 3′ coding region of the cDNA.
  • a PCR fragment encoding the modified finger-2 was made in a standard PCR reaction, using a commercially available PCR kit and following the manufacturer's instructions using as primers synthetic oligonucleotides.
  • a forward primer (primer #1) of the sequence GCG CCC ACG CAG CTC AGC GCT ATC TCC GTC CTC (SEQ ID NO: 70) was used, encoding the amino acid sequence: A P T Q L S A I S V L (SEQ ID NO: 71).
  • a back-primer 43 nucleotides long, (primer #2) was used which introduced the R25>E and N26>D and R30>E and C-terminal H35>R changes.
  • This primer #2 had the sequence: CTA TCT GCA GCC ACA AGC TTC GAC CAC CAT GTC TTC GTA TTT C (SEQ ID NO: 72) which is the complement of the coding sequence, G AAA TAC GAA GAC ATG GTG GTC GAA GCT TGT GGC TGC AGA TAG (SEQ ID NO: 73) encoding the amino acids: K Y E D M V V E A C G C R stop (SEQ ID NO: 74).
  • the fragment with finger 2 and C-terminus mutations was then combined with another PCR fragment encoding the upstream part of mature OP-1, with N-terminus, finger-1 and heel sub-domains.
  • the latter PCR fragment, encoding the N-terminus, finger 1 and heel sub-domains was constructed again using an OP-1 expression vector for E. coli as template.
  • the vector contained an OP-1 cDNA fragment, encoding the mature OP-1 protein attached to a T7 promoter and ribosome binding site for expression under control of either a T7 promoter in an appropriate host or under control of a trp promoter.
  • This second PCR reaction was primed with a forward primer (primer #3) TAA TAC GAC TCA CTA TAG G (SEQ ID NO: 76) which primes in the T7 promoter region and a back-primer (primer #4) that overlaps with primer #1 and has the nucleotide sequence GCT GAG CTG CGT GGG CGC (SEQ ID NO: 77), which is the complement of the coding sequence GCG CCC ACG CAG CTC AGC (SEQ ID NO: 78), encoding A P T Q L S (SEQ ID NO:79).
  • primer #3 was used as forward primer and a new primer (primer #5) was used as a back-primer with the following sequence GG ATC CTA TCT GCA GCC ACA AGC (SEQ ID NO: 80), which is the complement to coding sequence GCT TGT GGC TGC AGA TAG GAT CC (SEQ ID NO: 81), encoding A C G C R stop (SEQ ID NO: 82).
  • This primer also adds a convenient 3′ BamHI site for of inserting the gene into the expression vector.
  • the resulting fragment bearing the complete mutant gene, resulting from the overlap extension PCR was cloned into a commercial cloning vector designed for cloning of PCR fragments, such as pCR2.1-topo-TA (Invitrogen Inc., Carlsbad Calif.).
  • the cloned PCR fragment was recovered by restriction digest with XbaI and BamHI and inserted into the XbaI and BamHI sites of a commercially available T7 expression vector such as Pet3d (Novagen Inc., Madison Wis.).
  • Transformed cells were grown in standard SPYE 2YT media, 1:1 ratio, (see, Sambrook et al., for example) at 37° C., under standard culturing conditions.
  • Heterologous protein overexpression typically produced inclusion bodies within 8-48 hours. Inclusion bodies were isolated and solubilized as follows.
  • One liter of culture fluid was centrifuged to collect the cells.
  • the cells in the resulting pellet then were resuspended in 60 ml 25 mM Tris, 10 mM EDTA, pH 8.0 (TE Buffer)+100 ⁇ g/ml lysozyme and incubated at 37° C. for 2 hours.
  • the cell suspension was then chilled on ice and sonicated to lyse the cells.
  • Cell lysis was ascertained by microscopic examination. The volume of the lysate was adjusted to approximately 300 ml with TE Buffer, then centrifuged to obtain an inclusion body pellet. The pellet was washed by 2-4 successive resuspensions in TE Buffer and centrifugation. The washed inclusion body pellet was solubilized by denaturation and reduction in 40 ml 100 mM Tris, 10 mM EDTA, 6M GuHCl (guanidinium hydrochloride), 250 mM DTT, pH 8.8. Proteins then were pre-purified using a standard, commercially available C2 or C8 cartridge (SPICE cartridges, 400 mg, Ananltech, Inc.).
  • SPICE cartridges 400 mg, Ananltech, Inc.
  • Protein solutions were acidified with 2% TFA (trifluoroacetic acid), applied to the cartridge, washed with 0.1% TFA/10% acetonitrile, and eluted with 0.1% TFA/70% acetonitrile. The eluted material then was dried down or diluted and fractionated by C4 RP-HPLC.
  • TFA trifluoroacetic acid
  • Proteins prepared as described above were dried down prior to refolding, or diluted directly into refolding buffer.
  • the preferred refolding buffer used was: 100 mM Tris, 10 mM EDTA, 1 M NaCl, 2% CHAPS, 5 mM GSH (reduced glutathione), 2.5 mM GSSG (oxidized glutathione), pH 8.5.
  • Refoldings (12.5-200 ⁇ g protein/ml) were carried out at 4° C. for 24-90 hours, typically 36-48 hours, although longer than this (up to weeks) are expected to provide good refolding in some mutants, followed by dialysis against 0.1% TFA, then 0.01% TFA, 50% ethanol. Aliquots of the dialyzed material then was dried down in preparation for the various assays.
  • samples were chromatographed on a commercially available RP-HPLC, as follows. Samples were dried down and resuspended in 0.1% TFA/30% acetonitrile. The protein then was applied to a C18 column in 0.1% TFA, 30% acetonitrile and fractionated using a 30-60% acetonitrile gradient in TFA. Properly folded dimers elute as a discrete peak at 45-50% acetonitrile; monomers elute at 50-60% acetonitrile.
  • Trypsin Digest Tryptic digests were performed in a digestion buffer of 50 mM Tris, 4 M urea, 100 mM NaCl, 0.3% Tween 80, 20 mM methylamine, pH 8.0. The ratio of enzyme to substrate was 1:50 (weight to weight). After incubation at 37° C. for 16 hours, 15 ⁇ l of digestion mixture was combined with 5 ⁇ l 4 ⁇ gel sample buffer without DTT and analyzed by SDS-PAGE. Purified mammalian OP-1 and undigested BMP dimer were included for comparison. Under these conditions, properly folded dimers are cleaved to produce a species with slightly faster migration than uncleaved standards, while monomers and mis-folded dimers are completely digested and do not appear as bands in the stained gel.
  • This example demonstrates the bioactivity of morphogen constructs which have acquired osteogenic or bone-forming capabilities in accordance with the present invention.
  • Osteogenic proteins having either an inuate ability or an acquired ability for high specific bone forming activity can induce alkaline phosphatase activity in rat osteoblasts, including rat osteosarcoma cells and rat calveria cells.
  • rat osteosarcoma or calveria cells were plated onto a multi-well plate (e.g., a 48 well plate) at a concentration of 50,000 osteoblasts per well, in ⁇ MEM (modified Eagle's medium, Gibco, Inc. Long Island) containing 10% FBS (fetal bovine serum), L-glutamine and penicillin/streptomycin. The cells were incubated for 24 hours at 37° C., at which time the growth medium was replaced with a MEM containing 1% FBS and the cells incubated for an additional 24 hours so that cells were in serum-deprived growth medium at the time of the experiment.
  • Cultured cells then were divided into three groups: (1) wells receiving various concentrations of biosynthetic ostegenic protein; (2) a positive control, such as mammalian expressed hOP-1; and a negative control (no protein or TGF- ⁇ ).
  • the protein concentrations tested were in the range of 50-500 ng/ml.
  • Cells were incubated for 72 hours. After the incubation period the cell layer was extracted with 0.5 ml of 1% TritonX-100. The resultant cell extract was centrifuged, 100 ⁇ l of the extract was added to 90 ⁇ l of PNPP (paranitrosophenylphosphate)/glycerine mixture and incubated for 30 minutes in a 37° C.
  • PNPP paranitrosophenylphosphate
  • alkaline phosphatase activity was calculated in units/ ⁇ g protein, where 1 unit equals 1 nmol p-nitrophenol liberated/30 minutes at 37° C.
  • HOP-1 and BMP2 generate approximately 1.0-1.4 units at between 100-200 ng/ml. Other results are provided in Table 1 for the various protein constructs.
  • This example demonstrates the bioactivity of constructs which have acquired enhanced tissue morphogenic capabilities in accordance with the present invention.
  • Native CDMPs fail to induce alkaline phosphatase activity in rat osteosarcoma cells as used in Example 5, but they do induce alkaline phosphatase activity in the mouse teratocarcinoma cell line ATDC-5, a chondroprogenitor cell line (Atsumi, et al., 1990, Cell Differentiation and Development 30: 109).
  • Folded mutants that are negative in the rat osteocarcinoma cell assay but positive in the ATDC-5 assay are described as having acquired CDMP-like activity.
  • BM Ham's F-12/DMEM [1:1] with ITSTM+culture supplement [Collaborative Biomedical Products, Bedford, Mass.], alpha-ketoglutarate (1 ⁇ 10 ⁇ 4 M), ceruloplasmin (0.25 U/ml), cholesterol (5 ⁇ g/ml), phosphatidylethanolamine (2 ⁇ g/ml), alpha-tocopherol acid succinate (9 ⁇ 10 ⁇ 7 M), reduced glutathione (10 ⁇ g/ml), taurine (1.25 ⁇ g/ml), triiodothyronin (1.6 ⁇ 10 ⁇ 9 M), parathyroid hormone (5 ⁇ 10 ⁇ 10 M), ⁇ -glycerophosphate (10 mM), and L-ascorbic acid 2-sulphate (50 ⁇ g/ml)).
  • BM Ham's F-12/DMEM [1:1] with ITSTM+culture supplement [Collaborative Biomedical Products, Bedford, Mass.], alpha-ketoglutarate (1 ⁇ 10 ⁇ 4 M), ce
  • CDMP or other biosynthetic osteogenic protein (0-300 ng/ml) was added the next day and the culture medium, including CDMP or biosynthetic osteogenic protein, replaced every other day.
  • Alkaline phosphatase activity was determined in sonicated cell homogenates after 4, 6 and/or 12 days of treatment. After extensive washing with PBS, cell layers were sonicated in 500 ⁇ l of PBS containing 0.05% Triton-X100. 50-100 ⁇ l aliquots were assayed for enzyme activity in assay buffer (0.1M sodium barbital buffer, pH 9.3) and p-nitrophenyl phosphate as substrate. Absorbance was measured at 400 nm, and activity normalized to protein content measured by Bradford protein assay (bovine serum albumin standard).
  • CDMP-1 and CDMP-2 generated approximately 2-3 units of activity at day 10 at 100 ng/ml.
  • OP-1 generated approximately 6-7 units of activity at day 10 at 100 ng/ml.
  • TGF- ⁇ proteins can inhibit epithelial cell proliferation.
  • Numerous cell inhibition assays are well described in the art. See, for example, Brown, et. al. (1987) J. Immunol. 139:2977, describing a colorimetric assay using human melanoma A375 fibroblast cells, and described herein below.
  • Another assay uses epithelial cells, e.g., mink lung epithelial cells, and proliferative effects are determined by 3 H-thymidine uptake.
  • the TGF- ⁇ biosynthetic construct is serially diluted in a multi-well tissue plate containing RPMI-1640 medium (Gibco) and 5% fetal calf serum. Control wells receive medium only. Melanoma cells then are added to the well (1.5 ⁇ 10 4 ). The plates then are incubated at 37° C. for about 72 hours in 5% CO 2 , and the cell monolayers washed once, fixed and stained with crystalviolet for 15 minutes.
  • mink lung cells are used. These cells grow and proliferate under standard culturing conditions, but are arrested following exposure to TGF- ⁇ , as determined by 3 H-thymidine uptake using culture cells from a mink lung epithelial cell line (ATTC No. CCL 64, Rockville, Md.). Briefly cells are grown to confluency with in EMEM, supplemented with 10% FBS, 200 units/ml penicillin, and 200 ⁇ g/ml streptomycin. These cells are cultured to a cell density of about 200,000 cells per well. At confluency the media is replaced with 0.5 ml of EMEM containing 1% FBS and penicillin/streptomycin and the culture incubated for 24 hours at 37° C.
  • EMEM fetal bovine serum
  • Candidate proteins then are added to each well and the cells incubated for 18 hours at 37° C. After incubation, 1.0 ⁇ Ci of 3 H-thymidine in 10 ⁇ l was added to each well, and the cells incubated for four hours at 37° C. The media then is removed from each well and the cells washed once with ice-cold phosphate buffered saline and DNA precipitated by adding 0.5 ml of 10% TCA to each well and incubated at room temperature for 15 minutes.
  • the cells are washed three times with ice-cold distilled water, lysed with 0.5 ml 0.4 M NaOH, and the lysate from each well then transferred to a scintillation vial and the radioactivity recorded using a scintillation counter (Smith-Kline Beckman).
  • Biologically active molecules will inhibit cell proliferation resulting in less thymidine uptake and fewer counts as compared to inactive proteins and/or the negative control well (no added growth factor).
  • the art-recognized bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80:6591-6595) and U.S. Pat. Nos. 4,968,590, 5,266,683, the disclosures of which is herein incorporated by reference, can be used to establish the efficacy of a given protein, device or formulation.
  • the assay consists of depositing test samples in subcutaneous sites in recipient rats under ether anesthesia. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection.
  • the desired amount of osteogenic protein (10 ng-10 ⁇ g) is mixed with approximately 25 mg of matrix material, prepared using standard procedures such as lyophilization, and the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip.
  • the heterotropic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.
  • the implants also can be provided intramuscularly which places the devices in closer contact with accessable progenitor cells. Typically intramuscular implants are made in the skeletal muscle of both legs.
  • the sequential cellular reactions occurring at the heterotropic site are complex.
  • the multistep cascade of endochondral bone formation includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.
  • Successful implants exhibit a controlled progression through the stages of protein-induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one.
  • Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Staining with toluidine blue or hemotoxylin/eosin clearly demonstrates the ultimate development of endochondral bone. Twelve day bioassays are sufficient to determine whether bone inducing activity is associated with the test sample.
  • alkaline phosphatase activity and/or total calcium content can be used as biochemical markers for osteogenesis.
  • the alkaline phosphatase enzyme activity can be determined spectrophotometrically after homogenization of the excised test material. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Samples showing no bone development by histology should have no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation very quickly after the test samples are removed from the rat.
  • the results as measured by alkaline phosphatase activity level and histological evaluation can be represented as “bone forming units”. One bone forming unit represents the amount of protein that is needed for half maximal bone forming activity on day 12.
  • dose curves can be constructed for bone inducing activity in vivo at each step of a purification scheme by assaying various concentrations of protein. Accordingly, the skilled artisan can construct representative dose curves using only routine experimentation.
  • Total calcium content can be determined after homogenization in, for example, cold 0.15M NaCl, 3 mM NaHCO 3 , pH 9.0, and measuring the calcium content of the acid soluble fraction of sediment.
  • Domain swapping occurs, for example, when one takes the N-terminal region of one type of TGF- ⁇ family member protein and attaches it to the seven cysteine domain of another type of TGF- ⁇ family member protein.
  • a mutant construct was created by splicing the sequence of the BMP-2 terminus onto the seven cysteine active domain of OP-1 using routine techniques generally known to those of ordinary skill in the art.
  • the resulting mutant, H2549 has an N-terminal region consisting of MQAKHKQRKRLKSS-C.
  • the last amino acid, cysteine is the first cysteine of the seven cysteine active domain of OP-1.
  • a ROS assay as described above in Example 5, was used to test activity of H2549.
  • the results show that H2549 has very low activity as compared to the level of activity of OP-1.
  • ROS activity is significantly increased.
  • the activity of TGF- ⁇ family member proteins can be selectively controlled by attaching non-native N-terminal sequences to inactivate it and cleaving the non-native sequences to activate it.
  • Construct H2223 is a modified OP-1 mutant expressed in CHO cells. Two HPLC fractions of H2223 were collected, fractions 13 and 14. An amount of each fraction was truncated by trypsin cleavage, in a manner similar to that used upon dimers in Example 4. The four resulting samples, i.e., fractions 13 and 14 untreated with trypsin and fractions 13 and 14 treated with trypsin, were then subjected to a ROS assay, as described in Example 5 above, using OP-1 activity as the standard.
  • fractions 14 treated and untreated with trypsin are relatively the same. This is explained by fraction 14 being composed of partially truncated H2223 and, thus, further truncation with trypsin does not alter activity.
  • untreated fraction 13 is composed of mainly full length H2223 (i.e., the entire N-terminus of 39 amino acids) and truncation of the N-terminus of fraction 13 does increase ROS activity to levels comparable to those of fraction 14.
  • These activity levels are well above the ROS activity level of the OP-1 standard, and demonstrate that improvements in activity obtained with the modified proteins of the present invention.
  • H2440, OP-1 with a hexa-his N-terminus, and H2142, BMP-2 were allowed to form heterodimers and homodimers using the method as described in Example 3 above.
  • Heterodimers of H2440/2142, and homodimers of H2440/2440 and H2142/2142 were then subjected to a ROS assay, as described in Examples 4 and 5 above.
  • the homodimers of H2440, OP-1 with a hexa-his at the N-terminal have very low activity.
  • the homodimers of H2142, BMP-2 have better activity, but activity is still relatively low.
  • the heterodimer, OP-1 hexa-his and BMP-2 have far greater activity than either of the homodimers.
  • the heterodimers have only 3-fold less activity than the CHO derived OP-1.
  • homodimers and heterodimers were created between H2525, OP-1 with FB leader sequence, and H2142, BMP-2. These were also subjected to a ROS assay with the level of OP-1 activity as the standard. As illustrated in FIG. 14 , homodimers of H2525, OP-1 with FB, have virtually no activity and homodimers of H2142, BMP-2, have very low activity. In contrast, heterodimers of the two, H2525/2142, have unexpectedly high activity levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US10/816,768 1998-10-07 2004-04-02 Modified TGF-beta superfamily proteins Abandoned US20050250936A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/816,768 US20050250936A1 (en) 1998-10-07 2004-04-02 Modified TGF-beta superfamily proteins
US11/715,679 US8518411B2 (en) 1998-10-07 2007-03-07 Modified TGF-β superfamily protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10341898P 1998-10-07 1998-10-07
US37533399A 1999-08-16 1999-08-16
US10/816,768 US20050250936A1 (en) 1998-10-07 2004-04-02 Modified TGF-beta superfamily proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US37533399A Continuation 1998-10-07 1999-08-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/715,679 Continuation US8518411B2 (en) 1998-10-07 2007-03-07 Modified TGF-β superfamily protein

Publications (1)

Publication Number Publication Date
US20050250936A1 true US20050250936A1 (en) 2005-11-10

Family

ID=26800442

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/816,768 Abandoned US20050250936A1 (en) 1998-10-07 2004-04-02 Modified TGF-beta superfamily proteins
US11/715,679 Expired - Fee Related US8518411B2 (en) 1998-10-07 2007-03-07 Modified TGF-β superfamily protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/715,679 Expired - Fee Related US8518411B2 (en) 1998-10-07 2007-03-07 Modified TGF-β superfamily protein

Country Status (6)

Country Link
US (2) US20050250936A1 (fr)
EP (2) EP2128260A3 (fr)
JP (6) JP3762222B2 (fr)
AU (1) AU1103900A (fr)
CA (2) CA2345024C (fr)
WO (1) WO2000020449A2 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037469A1 (en) * 1999-07-21 2005-02-17 University Of Southern California, A California Corporation Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US20080199443A1 (en) * 2005-06-09 2008-08-21 The Govt. Of The U.S.A. As Represented By The Secretary, Dept. Of Health And Human Services Bone Morphogenetic Variants, Compositions and Methods of Treatment
US20090305352A1 (en) * 2005-12-26 2009-12-10 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
US20110206759A1 (en) * 2010-02-11 2011-08-25 Swartz Melody A Ccr7 ligand delivery and co-delivery in immunotherapy
WO2011119833A2 (fr) * 2010-03-24 2011-09-29 Lifenet Health Peptides bmp-7 et procédés d'utilisation
WO2012021512A2 (fr) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Agents thérapeutiques se liant aux érythrocytes
WO2013121296A1 (fr) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Agents thérapeutiques se liant aux érythrocytes
US8772236B2 (en) 2009-02-06 2014-07-08 Pepscan Systems B.V. Truncated cystine-knot proteins
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2017209519A1 (fr) * 2016-05-31 2017-12-07 Mogam Institute For Biomedical Research Ligands sur mesure de la famille ab6 de la superfamille tgf-bêta
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10821157B2 (en) 2014-02-21 2020-11-03 Anokion Sa Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US7141392B2 (en) 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
FI116827B (fi) 2001-08-24 2006-03-15 Univ Zuerich Luun morfogeneettisen proteiinin deleetiomutantti, sitä sisältävä farmaseuttinen koostumus ja sen käyttö
JP5448338B2 (ja) 2004-04-13 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 食欲を調節する方法
WO2005113585A2 (fr) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Superfamille des polypeptides tgf-beta modifiés et procédés atenants
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
WO2008051526A2 (fr) * 2006-10-23 2008-05-02 Stryker Corporation Protéines morphogénétiques osseuses
EP2120859B1 (fr) 2006-12-21 2013-11-20 Stryker Corporation Formulations à libération entretenue comprenant des cristaux de bmp-7
US20100204124A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
CN102369016A (zh) 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
WO2010110974A1 (fr) 2009-03-24 2010-09-30 Stryker Corporation Procédés et compositions pour l'ingénierie tissulaire
WO2011031856A1 (fr) 2009-09-09 2011-03-17 Stryker Corporation Bmp-7 à utiliser dans le traitement de la douleur induite par les lésions et les maladies d'articulation
WO2011035094A1 (fr) 2009-09-17 2011-03-24 Stryker Corporation Tampons utilisés pour la régulation du ph des protéines morphogénétiques osseuses
AU2010341565A1 (en) 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
BR112013003587B1 (pt) * 2010-08-20 2022-11-08 Wyeth Llc Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
JP2019502674A (ja) * 2015-08-25 2019-01-31 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5658882A (en) * 1993-12-07 1997-08-19 Genetics Institute, Inc. Methods of inducting formation of tendon and/or ligament tissue comprising administering BMP-12, BMP-13, and/or MP-52
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US5770444A (en) * 1993-07-09 1998-06-23 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
US5801014A (en) * 1993-01-12 1998-09-01 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US5807713A (en) * 1992-02-12 1998-09-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung DNA encoding growth/differentiation factor
US5840325A (en) * 1988-04-08 1998-11-24 Stryker Corporation Osteogenic devices
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002198A1 (fr) * 1983-11-01 1985-05-23 Amgen Expression microbienne du facteur de croissance transformant du type i, de ses analogues polypeptidiques et des polypeptides hybrides de l'egf et du tgf
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5108922A (en) 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5155058A (en) 1986-11-07 1992-10-13 Canon Kabushiki Kaisha Method of making semiconductor memory device
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
EP0372005A4 (fr) * 1987-10-30 1990-06-26 Oncogen Systemes d'expression destines a la preparation de polypeptides dans des cellules procaryotiques.
US5258494A (en) 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
EP0448704B1 (fr) 1989-10-17 1998-06-17 Stryker Corporation Dispositifs osteogenes
AU6870791A (en) * 1989-10-18 1991-05-16 Creative Biomolecules, Inc. Biosynthetic constructs of tgf-beta
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
CA2084992A1 (fr) * 1990-06-25 1991-12-26 Osi Pharmaceuticals, Inc. Inhibiteurs de croissance tumorale derives de tissus, mode de preparation et utilisations
ES2161693T3 (es) 1991-03-11 2001-12-16 Curis Inc Morfogenesis inducida por proteinas.
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
SK285035B6 (sk) 1992-10-28 2006-05-04 Genentech, Inc. Antagonisty rastového faktora vaskulárnych endotelových buniek
EP0626451A3 (fr) * 1993-05-27 1997-11-05 Takeda Chemical Industries, Ltd. Hétérodimères d'une superfamille de TGF-bêta
TW459044B (en) * 1994-07-01 2001-10-11 Bioph Biotech Entw Pharm Gmbh Protein MP-121 of the TGF-β-like family
US5932716A (en) 1995-07-26 1999-08-03 Creative Biomolecules, Inc. Morphogen-responsive regulatory elements
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US8750953B2 (en) 2008-02-19 2014-06-10 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
MX343525B (es) 2008-04-29 2016-11-09 Immunexcite Inc Composiciones inmunomoduladoras y metodos de uso de las mismas.
WO2011025042A1 (fr) 2009-08-31 2011-03-03 新日本製鐵株式会社 Feuille d'acier galvanisé à chaud très résistante et son procédé de production
US9201968B2 (en) 2011-08-29 2015-12-01 Massachusetts Institute Of Technology System and method for finding mood-dependent top selling/rated lists
US9107654B2 (en) 2012-01-05 2015-08-18 Cook Medical Technologies Llc Attachment device for tissue approximation and retraction

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5840325A (en) * 1988-04-08 1998-11-24 Stryker Corporation Osteogenic devices
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5807713A (en) * 1992-02-12 1998-09-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung DNA encoding growth/differentiation factor
US5801014A (en) * 1993-01-12 1998-09-01 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
US5770444A (en) * 1993-07-09 1998-06-23 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
US5658882A (en) * 1993-12-07 1997-08-19 Genetics Institute, Inc. Methods of inducting formation of tendon and/or ligament tissue comprising administering BMP-12, BMP-13, and/or MP-52
US5756308A (en) * 1993-12-07 1998-05-26 Genetics Institute, Inc. Refolding variant of bone morphogenetic protein-8
US5804416A (en) * 1993-12-07 1998-09-08 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037469A1 (en) * 1999-07-21 2005-02-17 University Of Southern California, A California Corporation Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US7459541B2 (en) * 1999-07-21 2008-12-02 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US20090093407A1 (en) * 1999-07-21 2009-04-09 Hall Frederick L Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US20080199443A1 (en) * 2005-06-09 2008-08-21 The Govt. Of The U.S.A. As Represented By The Secretary, Dept. Of Health And Human Services Bone Morphogenetic Variants, Compositions and Methods of Treatment
US9359403B2 (en) 2005-12-26 2016-06-07 Yantai Zhenghai Bio-Tech Co., Ltd Activated collagen scaffold materials and their special fused active restoration factors
US8802396B2 (en) * 2005-12-26 2014-08-12 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
US20090305352A1 (en) * 2005-12-26 2009-12-10 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
US9365617B2 (en) 2005-12-26 2016-06-14 Yantai Zhenghai Bio-Tech Co., Ltd Activated collagen scaffold materials and their special fused active restoration factors
US8772236B2 (en) 2009-02-06 2014-07-08 Pepscan Systems B.V. Truncated cystine-knot proteins
US20110206759A1 (en) * 2010-02-11 2011-08-25 Swartz Melody A Ccr7 ligand delivery and co-delivery in immunotherapy
US8592364B2 (en) 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
WO2011119833A2 (fr) * 2010-03-24 2011-09-29 Lifenet Health Peptides bmp-7 et procédés d'utilisation
WO2011119833A3 (fr) * 2010-03-24 2011-12-29 Lifenet Health Peptides bmp-7 et procédés d'utilisation
US9926357B2 (en) 2010-03-24 2018-03-27 Lifenet Health BMP-7 peptides and methods of use
US9901646B2 (en) 2010-08-10 2018-02-27 Ecole Polytechnique Federale De Lausanne (Epfl) Methods for induction of antigen-specific immune tolerance
US10471155B2 (en) 2010-08-10 2019-11-12 École Polytechnique Fédérale De Lausanne (Epfl) Antigen-specific tolerance and compositions for induction of same
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US11884721B2 (en) 2010-08-10 2024-01-30 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US11246943B2 (en) 2010-08-10 2022-02-15 École Polytechnique Fédérale De Lausanne (Epfl) Antigen-specific tolerance and compositions for induction of same
WO2012021512A2 (fr) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Agents thérapeutiques se liant aux érythrocytes
US10919963B2 (en) 2010-08-10 2021-02-16 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9814780B2 (en) 2010-08-10 2017-11-14 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions for inducing antigen-specific tolerance
US10800838B2 (en) 2010-08-10 2020-10-13 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9878048B2 (en) 2010-08-10 2018-01-30 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions for generating immune tolerance by targeting erythrocytes
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9901645B2 (en) 2010-08-10 2018-02-27 Ecole Polytechnique Fedrale de Lausanne (EPFL) Methods for reducing immune responses
US10392437B2 (en) 2010-08-10 2019-08-27 École Polytechnique Fédérale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10265415B2 (en) 2010-08-10 2019-04-23 École Polytechnique Fédérale De Lausanne (Epfl) Compositions for inducing antigen-specific tolerance
US10265416B2 (en) 2010-08-10 2019-04-23 École Polytechnique Fédérale de Lausanna (EPFL) Compositions for generation of immune tolerance to specific antigens
WO2013121296A1 (fr) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Agents thérapeutiques se liant aux érythrocytes
US9758576B2 (en) 2013-05-06 2017-09-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US11827698B2 (en) 2013-05-06 2023-11-28 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9580500B2 (en) 2013-05-06 2017-02-28 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10597443B2 (en) 2013-05-06 2020-03-24 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9758577B2 (en) 2013-05-06 2017-09-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10981981B2 (en) 2013-05-06 2021-04-20 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10821157B2 (en) 2014-02-21 2020-11-03 Anokion Sa Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10940209B2 (en) 2014-02-21 2021-03-09 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11666638B2 (en) 2014-02-21 2023-06-06 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11801305B2 (en) 2014-02-21 2023-10-31 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11793882B2 (en) 2014-02-21 2023-10-24 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11654188B2 (en) 2014-02-21 2023-05-23 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
WO2017209519A1 (fr) * 2016-05-31 2017-12-07 Mogam Institute For Biomedical Research Ligands sur mesure de la famille ab6 de la superfamille tgf-bêta
US11512126B2 (en) 2016-05-31 2022-11-29 Mogam Institute For Biomedicak Research AB6 family designer ligands of TGF-β superfamily
KR102404717B1 (ko) 2016-05-31 2022-05-31 재단법인 목암생명과학연구소 Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드
KR20190025569A (ko) * 2016-05-31 2019-03-11 재단법인 목암생명과학연구소 Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Also Published As

Publication number Publication date
JP2005320339A (ja) 2005-11-17
WO2000020449A3 (fr) 2000-10-12
JP2010180241A (ja) 2010-08-19
US20120122778A1 (en) 2012-05-17
WO2000020449A9 (fr) 2002-08-22
WO2000020449A2 (fr) 2000-04-13
AU1103900A (en) 2000-04-26
CA2345024C (fr) 2009-05-19
JP3762222B2 (ja) 2006-04-05
EP1117805A2 (fr) 2001-07-25
JP2013014606A (ja) 2013-01-24
EP2128260A2 (fr) 2009-12-02
EP2128260A3 (fr) 2010-06-16
JP2008231125A (ja) 2008-10-02
JP2016056185A (ja) 2016-04-21
US8518411B2 (en) 2013-08-27
CA2345024A1 (fr) 2000-04-13
CA2657302A1 (fr) 2000-04-13
JP2003535019A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
US8518411B2 (en) Modified TGF-β superfamily protein
US6677432B1 (en) Mutations of the C-terminal portion of TGF-β superfamily proteins
JP2005287515A (ja) 形態形成タンパク質を含むＴＧＦ−βスーパーファミリー変異体メンバー
AU717811B2 (en) Single chain analogs of the TGF-beta superfamily (morphons)
AU770494B2 (en) Single chain analogs of the TGF-beta superfamily (morphons)

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION